Topical therapy for treating skin malignancies using taxane nanoparticles

By using a hydrophobic composition of taxane nanoparticles, the problems of poor permeability and high irritation in local treatment of skin cancer and skin metastases have been solved, achieving a low-irritation and high-permeability local treatment effect.

CN118948828APending Publication Date: 2024-11-15DFB SORIA LLC
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411017512.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2017-03-15
Filing Date
2018-03-15
Publication Date
2024-11-15

AI Technical Summary

Technical Problem

Existing methods for local treatment of skin cancer and skin metastases suffer from poor permeability, high irritation, and the need to be combined with other therapies, resulting in limited treatment efficacy and poor patient compliance.

Method used

A hydrophobic composition containing taxane nanoparticles is used, which enhances drug permeability by utilizing a hydrophobic carrier and volatile silicone fluid, avoiding the use of volatile solvents and surfactants, reducing skin irritation, and enabling the drug to directly penetrate into the epidermis and dermis of the skin.

Benefits of technology

It achieves low-irritation and effective local treatment. The increased permeability of taxane nanoparticles in the skin reduces systemic absorption, enhances the therapeutic effect, and does not depend on other skin-targeted therapies.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN118948828A_ABST
    Figure CN118948828A_ABST
Patent Text Reader

Abstract

Disclosed are methods for the topical treatment of skin malignancies, including skin cancer and skin metastases, using compositions containing paclitaxel or other taxane nanoparticles.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of an invention patent application with an application date of March 15, 2018, application number 201880032503.3, and invention name “Local therapy for treating skin malignancies using taxane nanoparticles”.

[0002] CROSS-REFERENCE TO RELATED APPLICATIONS

[0003] This application claims the benefit of U.S. Provisional Application No. 62 / 471,561, filed on March 15, 2017. The contents of the referenced application are incorporated herein by reference. Technical Field

[0004] The present invention relates generally to the field of topical treatment of skin malignancies including skin cancer and skin metastases. In particular, the present invention relates to the use of a topical composition comprising taxane nanoparticles in the treatment of skin malignancies. Background Art

[0005] Skin malignancies include skin cancer and skin metastases. Skin cancer forms in skin tissue. There are several types of skin cancer, including melanoma (malignant melanoma), basal cell carcinoma, squamous cell carcinoma, neuroendocrine cancer of the skin, Merkel cell tumor, dermatofibrosarcoma protuberans and Kaposi's sarcoma. The main types of skin cancer include melanoma, basal cell carcinoma and squamous cell carcinoma. Melanoma is a skin cancer that forms in melanocytes (pigment-forming skin cells). Basal cell carcinoma forms in the lower part of the epidermis, and squamous cell carcinoma forms in squamous cells. Neuroendocrine cancer of the skin forms in neuroendocrine cells. The vast majority of skin cancers are basal cell carcinoma and squamous cell carcinoma, and they usually do not spread to other parts of the body (metastasis). Melanoma tends to spread to other parts of the body. Kaposi's sarcoma is a relatively rare skin malignancy that troubles the elderly or people with abnormal immune systems, such as AIDS patients. Kaposi's sarcoma is a lesion (tumor) of the skin characterized by soft purple plaques and papules that form nodules on the skin.

[0006] Skin metastases refer to cancer cells originating from internal cancer or skin cancer (e.g., melanoma) growing in the skin. When cancer cells break away from the primary tumor and usually reach the skin through the blood circulation or lymphatic system, skin metastases occur. Skin metastases have been reported to be clinical manifestations of the following cancers: breast cancer, lung cancer, sinus cancer, laryngeal cancer, oral cancer, colorectal cancer, gastric cancer, ovarian cancer, testicular cancer, bladder cancer, prostate cancer, cervical cancer, vaginal cancer, thyroid cancer, endometrial cancer, kidney cancer, esophageal cancer, pancreatic cancer, liver cancer, melanoma, and Kaposi's sarcoma (including Kaposi's sarcoma associated with AIDS). Skin metastases are becoming more and more common, with approximately 10% of patients experiencing metastatic cancer (Lookingbill et al., Cutaneous metastases in patients with metastatic carcinoma: A retrospective study of 4020 patients, J Am Acad Dermatol 29: 228-236, 1993). Women with skin metastases are distributed in descending order of frequency of primary malignancies as follows: breast, ovary, oral cavity, lung and large intestine. In men, the distribution is as follows: lung, large intestine, oral cavity, kidney, breast, esophagus, pancreas, stomach and liver. (Alcaraz et al., Cutaneous Metastases from Internal Malignancies: A Clinicopathologic and Immunohistochemical Review, Am J Dermatopathol 34: 347-393, 2012). With the advancement of cancer treatment, patients survive longer and are therefore more likely to develop skin metastases.

[0007] Typically, skin metastases are firm, round or oval lesions that are active, painless or with intact epidermis. Sometimes nodules ulcerate and become secondarily infected. Other signs of skin metastases are the presence of plaques, papules, or red macules. Skin metastases can cause pain, infection, bleeding, and / or disfigurement and may negatively impact the patient's quality of life.

[0008] The incidence of skin metastases in breast cancer patients has been reported recently to be 23.9% (Lookingbill et al.). Skin metastases from breast cancer are the most common metastases observed by dermatologists (De Giorgi et al., Cutaneous manifestations of breast carcinoma, Dermatol Therapy, 23:581-589, 2010). These skin metastases most often occur in the chest wall and abdomen, but may also occur in the limbs and head and neck regions. Nodules are the most common form of these skin metastases. Their size is 1cm to 3cm, and is a single or multiple lesions that are solid in the dermis or subcutaneous tissue.

[0009] A variety of therapies are available for skin cancer and skin metastases, including systemic therapy and skin-directed therapy. However, systemic therapy has limited efficacy in treating skin metastases (Spratt et al., Efficacy of Skin-Directed Therapy for Cutaneous Metastases from Advanced Cancer: A Meta-Analysis, J Clin Oncol, 32: 3144-3155, 2014).

[0010] Skin directed therapy includes electrochemotherapy (ECT), photodynamic therapy (PDT), radiotherapy (RT), intralesional therapy (ILT) and topical therapy. ECT, PDT, RT and ILT all need to be applied by a physician or technician, while topical therapy can be applied by the patient. Therefore, topical therapy can be cheaper than other therapies, and can also allow greater patient compliance because the therapy can be applied by the patient at home. However, the topical therapy response rate of the composition comprising imiquimod or miltefosine for the treatment of skin metastases is low, and only shows an improved response rate (Spratt et al.) when combined with other skin directed therapies. In a meta-analysis of 47 prospective studies of 4313 skin metastases, the objective response rate to the above-mentioned therapies (including radiotherapy) was 60.2% (Spratt et al.). ECT shows the best response rate (complete response rate of 47.5%); however, ECT is an inpatient procedure requiring general anesthesia and often results in significant pain and skin toxicity (inflammation, pigmentation, and ulceration) (Cabula et al., Electrochemotherapy in the Treatment of Cutaneous Metastases from Breast Cancer: A Multicenter Cohort Analysis, Ann Surg Oncol (2015) 22: S442-S450). Less invasive alternatives such as intralesional therapy and topical therapy show reduced efficacy compared to ECT. When effective reduction of skin metastases cannot be achieved (which is often the case), healthcare providers must rely on palliative wound care therapies (Fernandez-Anton Martinez et al., Metastasis cutáneas de origen visceral, Actas Dermosifiliogr. 2013; 104(10): 841-853). Therefore, it would be beneficial to have a topical therapeutic composition that can effectively treat skin metastases without combining with other skin-directed therapies. Thus, there is a significant unmet need for effective, less invasive alternative treatments for skin metastases in patients who already have significant morbidity from the symptoms and treatment of advanced primary cancer.

[0011] Due to the barrier properties of the stratum corneum (the outermost layer of the epidermis), it can be a challenge to deliver therapeutic drugs into the viable epidermis and dermis of the skin. It is even more challenging to deliver poorly water-soluble drugs into the skin. Skin penetration enhancers have been used in topical drug formulations to increase the penetration of drugs into the skin with some success. However, some penetration enhancers (such as solvents and surfactants) may irritate the skin. Volatile silicone fluids have been used in topical formulations to increase the penetration of drugs into the skin; however, high concentrations of volatile silicone fluids (i.e., 25% or greater) and / or volatile silicone fluids combined with other potentially irritating skin compounds (e.g., alcohols, such as C 1 To C 4 The combination of topical delivery systems (such as fatty alcohols, surfactants, other penetration enhancers and other volatile solvents) produces penetration enhancement. In addition, some penetration enhancers will cause the drug to penetrate the skin and be absorbed systemically, which is undesirable when only treating skin (e.g., epidermal and / or dermal) conditions. Other topical delivery systems have been used in which the drug is chemically modified with surfactants and other substances, but these substances can also irritate the skin.

[0012] Taxanes, including paclitaxel and docetaxel, have been used to treat cancer for many years. These compounds are generally poorly water soluble. They were originally developed for intravenous (IV) infusions as cancer treatments. (BMS) is dissolved in polyethoxylated castor oil ( In the present invention, paclitaxel is prepared in a 50 volume: 50 volume mixture of CREMOPHOR EL) and dehydrated ethanol. However, systemic use of this formulation has resulted in significant clinical toxicity (Rowinsky et al., 1993). A great deal of work has been devoted to developing paclitaxel formulations without CREMOPHOR EL (Ma and Mumper, 2013). One such formulation is disclosed in US8221779, which is incorporated herein by reference, which discloses an injectable aqueous composition of anti-mitotic drug microparticles containing paclitaxel, which can be used to treat cancer by intraperitoneal and intravenous (IV) injection of the composition.

[0013] Topical treatments for skin cancer currently include topical formulations of 5-fluorouracil (5-FU), imiquimod, and ingenol methylbutyrate. However, the use of these formulations can cause local skin irritation, such as burning, redness, dryness, pain, swelling, itching, tenderness, and ulceration at the site of application.

[0014] Currently, there are no FDA-approved topical taxane formulations for the treatment of skin cancer or skin metastases in the U.S. Previous topical treatments of skin metastases using compositions containing other active ingredients may be ineffective in part because the compositions are unable to penetrate the skin to the affected tissue. Summary of the invention

[0015] The present invention provides solutions to the aforementioned limitations and deficiencies in the field related to the treatment of skin malignancies including skin cancer and skin metastases. A topical therapy is disclosed that utilizes a topical composition with enhanced skin permeability to deliver taxane nanoparticles to skin malignancies including skin cancer and skin metastases, thereby providing effective treatment with low to negligible local skin irritation. In some cases, the treatment methods of the present invention can be used without combining them with other known skin-directed therapies (such as the therapies described above).

[0016] In one aspect of the present invention, a method of treating a skin malignancy in a subject in need of treatment is disclosed, the method comprising topically administering (topically applying) a composition comprising a plurality of taxane nanoparticles to an affected area of ​​the subject. An "affected area" of a skin malignancy may include at least a portion of the skin where a skin malignancy lesion is evident on the outermost surface of the skin or just below the skin surface (epithelial / dermal covering), and may include an area of ​​the skin near the skin malignancy that may contain visually undetectable preclinical lesions. In some embodiments, the taxane nanoparticles are suspended in the composition. In other embodiments, the taxane nanoparticles have an average particle size (number average) of 0.1 microns to 1.5 microns. In various embodiments, the taxane nanoparticles are paclitaxel nanoparticles, docetaxel nanoparticles, or cabazitaxel nanoparticles, or any combination of these nanoparticles. In some embodiments, the taxane nanoparticles are paclitaxel nanoparticles. In some embodiments, the specific surface area (SSA) of the paclitaxel nanoparticles is at least 18 m 2 / g, or 18m 2 / g to 40m 2 / g. The concentration of the taxane nanoparticles in the composition is a concentration that effectively provides an improvement in the treatment of a skin malignancy, which can be a skin cancer or a skin metastasis. In some embodiments, the effective concentration of the taxane nanoparticles or paclitaxel nanoparticles is about 0.15 wt % to about 2 wt %, or 0.1 wt % to 5 wt %. In some embodiments, the composition is anhydrous. In some embodiments, the composition is a hydrophobic composition and can include a hydrophobic carrier. In other embodiments, the hydrophobic carrier is non-volatile and / or non-polar. In various embodiments, the hydrophobic carrier includes a hydrocarbon, which can be a petrolatum, a mineral oil, or a paraffin or a mixture thereof. In some embodiments, the mineral oil is a heavy mineral oil. In some embodiments, the hydrophobic carrier is greater than 50 wt % of the composition. The hydrophobic composition may also include one or more than one volatile silicone fluid. In some embodiments, the concentration of the volatile silicone fluid is 5 wt % to 24 wt % of the composition, and the volatile silicone fluid can be cyclomethicone. In some embodiments, the cyclomethicone is cyclopentasiloxane. In various embodiments, the composition is a semisolid composition and may be an ointment. In various embodiments, the composition does not contain volatile C 1 To C 4 Fatty alcohol or C 1 To C 5 In some embodiments, the skin malignancy is skin cancer. In some embodiments, the skin cancer is melanoma, basal cell carcinoma, squamous cell carcinoma and / or Kaposi's sarcoma. In some embodiments, the skin malignancy is a skin metastasis. In some embodiments, the skin metastasis is from lung cancer, breast cancer, colon cancer, oral cancer, ovarian cancer, kidney cancer, esophageal cancer, gastric cancer and / or liver cancer; and / or Kaposi's sarcoma (including Kaposi's sarcoma associated with AIDS). In other embodiments, the treatment method does not include other skin-directed therapies.

[0017] In another aspect of the present invention, a method of enhancing penetration of taxane nanoparticles into a skin malignancy of a subject is disclosed, the method comprising topically applying a hydrophobic composition comprising a continuous hydrophobic carrier, one or more than one volatile silicone fluid, and a plurality of taxane nanoparticles to the affected area. In some embodiments, the taxane nanoparticles are suspended in the composition. In other embodiments, the taxane nanoparticles have an average particle size (number average) of 0.1 microns to 1.5 microns. In various embodiments, the taxane nanoparticles are paclitaxel nanoparticles, docetaxel nanoparticles, or cabazitaxel nanoparticles, or any combination of these nanoparticles. In some embodiments, the taxane nanoparticles are paclitaxel nanoparticles. In some embodiments, the specific surface area (SSA) of the paclitaxel nanoparticles is at least 18 m 2 / g, or 18m 2 / g to 40m 2 / g. In some embodiments, the concentration of taxane nanoparticles or paclitaxel nanoparticles is about 0.15 wt % to about 2 wt %, or 0.1 wt % to 5 wt %. In some embodiments, the composition is anhydrous. In some embodiments, the composition is a hydrophobic composition and can include a hydrophobic carrier. In other embodiments, the hydrophobic carrier is non-volatile and / or non-polar. In various embodiments, the hydrophobic carrier includes a hydrocarbon, which can be petrolatum, mineral oil or paraffin or a mixture thereof. In some embodiments, the mineral oil is a heavy mineral oil. In some embodiments, the hydrophobic carrier is greater than 50 wt % of the composition. The hydrophobic composition may also include one or more than one volatile silicone fluid. In some embodiments, the concentration of the volatile silicone fluid is 5 wt % to 24 wt % of the composition, and the volatile silicone fluid may be cyclomethicone. In some embodiments, cyclomethicone is cyclopentapolydimethylsiloxane. In various embodiments, the composition is a semi-solid composition and may be an ointment, and may have a viscosity of 25,000 cp to 500,000 cp, measured with a Brookfield RV viscometer on a lift stand with a TE spindle at 10 RPM, room temperature for 45 seconds. In various embodiments, the composition does not contain volatile C 1 To C 4 Fatty alcohol or C 1 To C 5In some embodiments, the skin malignancy is a skin cancer. In some embodiments, the skin cancer is a melanoma, a basal cell carcinoma, a squamous cell carcinoma, and / or a Kaposi's sarcoma. In some embodiments, the skin malignancy is a skin metastasis. In some embodiments, the skin metastasis is from lung cancer, breast cancer, colon cancer, oral cancer, ovarian cancer, kidney cancer, esophageal cancer, gastric cancer, and / or liver cancer; and / or Kaposi's sarcoma (including Kaposi's sarcoma associated with AIDS). In some embodiments, the penetration of taxane nanoparticles from the hydrophobic composition into the skin malignancy is greater than the penetration of taxane nanoparticles from a topically applied hydrophobic composition comprising a plurality of taxane nanoparticles and not comprising one or more than one volatile silicone fluid into the skin malignancy.

[0018] In another aspect of the present invention, a method of enhancing penetration of taxane nanoparticles into a skin malignancy of a subject is disclosed, the method comprising topically applying a hydrophobic composition comprising a plurality of taxane nanoparticles to an affected area, wherein penetration of the taxane nanoparticles from the hydrophobic composition into the skin malignancy is greater than penetration of the taxane nanoparticles from the topically applied aqueous composition comprising a plurality of taxane nanoparticles into the skin malignancy. In some embodiments, the taxane nanoparticles have an average particle size (number average) of 0.1 microns to 1.5 microns. In some embodiments, the taxane nanoparticles are paclitaxel nanoparticles, docetaxel nanoparticles, or cabazitaxel nanoparticles, or any combination of these nanoparticles. In some embodiments, the hydrophobic composition further comprises a hydrophobic carrier.

[0019] As disclosed in International Publication WO2017 / 049083 (Application PCT / US2016 / 052133), which is incorporated herein by reference, it was found that the hydrophobic compositions of the present invention having a volatile silicone fluid at a concentration of less than 25 wt % with an anhydrous hydrophobic carrier exhibited greater skin penetration (i.e., penetration into the epidermis and dermis of the skin) of the taxane nanoparticles compared to the skin penetration of the taxane nanoparticles from the hydrophobic carrier alone. Surprisingly, it was also found that, in addition to a small amount of volatile silicone fluid (less than 25 wt %), the addition of other skin penetration enhancers to the hydrophobic composition had little or no effect on the skin penetration of the composition. Therefore, the compositions of the present invention may not contain (need not contain) these additional skin penetration enhancers (e.g., surfactants, volatile solvents, alcohols, C 1 To C 4 Fatty alcohol or C 1 To C 5

[0013] The present invention also provides a skin permeation enhancer that helps reduce skin irritation when the compositions of the present invention are applied to the skin. Even more surprisingly, enhanced permeation is achieved with low concentrations of cyclomethicone, i.e., less than 25% by weight of cyclomethicone. In addition, the taxane nanoparticles are not initially delivered transdermally with these compositions after application, which is an advantageous feature because transdermal delivery (systemic absorption) is not desired when treating the skin (epidermis and dermis). Furthermore, the skin permeation (i.e., penetration into the dermis or epidermis portion of the skin) of the taxane nanoparticles from the compositions of the present invention is much better than the skin permeation of the taxane nanoparticles from aqueous compositions, even if the aqueous compositions contain a skin permeation enhancer. In addition, the taxane nanoparticles are found to be stable in the hydrophobic compositions of the present invention and do not exhibit crystal growth that varies over time.

[0020] Hydrophobic compositions comprising nanoparticles of a taxane (e.g., paclitaxel) and a volatile silicone fluid in combination with a hydrophobic carrier are particularly suitable for topical treatment of skin malignancies including skin cancer and skin metastases because these compositions have the aforementioned enhanced penetration into the epidermis and dermis of the skin. The hydrophobic carrier can be the continuous phase of the composition having the nanoparticles suspended therein.

[0021] The following embodiments 1 to 71 are also disclosed in the context of the present invention:

[0022] Embodiment 1 is a method of treating a cutaneous malignancy in a subject in need of such treatment, the method comprising topically administering a composition comprising a plurality of taxane nanoparticles to the affected area of ​​the subject.

[0023] Embodiment 2 is the method of embodiment 1, wherein the taxane nanoparticles are suspended in the composition.

[0024] Embodiment 3 is the method of any one of embodiments 1 to 2, wherein the taxane nanoparticles have an average particle size (number average) of 0.1 microns to 1.5 microns.

[0025] Embodiment 4 is the method of any one of embodiments 1 to 3, wherein the taxane nanoparticles are paclitaxel nanoparticles, docetaxel nanoparticles, or cabazitaxel nanoparticles.

[0026] Embodiment 5 is the method of embodiment 4, wherein the taxane nanoparticles are paclitaxel nanoparticles.

[0027] Embodiment 6 is the method of embodiment 5, wherein the paclitaxel nanoparticles have at least 18 m 2 / g specific surface area (SSA).

[0028] Embodiment 7 is the method of embodiment 6, wherein the paclitaxel nanoparticles have 18m 2 / g to 40m 2 / g specific surface area (SSA).

[0029] Embodiment 8 is the method of any one of embodiments 1 to 7, wherein the concentration of the taxane nanoparticles is a concentration effective to provide improved treatment of the skin malignancy.

[0030] Embodiment 9 is the method of embodiment 8, wherein the concentration of the paclitaxel nanoparticles is from about 0.15 wt % to about 2 wt %, or 0.1 wt % to 5 wt %.

[0031] Embodiment 10 is the method of any one of embodiments 1 to 9, wherein the composition is anhydrous.

[0032] Embodiment 11 is the method of any one of embodiments 1 to 10, wherein the composition is a hydrophobic composition.

[0033] Embodiment 12 is the method of embodiment 11, wherein the hydrophobic composition comprises a hydrophobic carrier.

[0034] Embodiment 13 is the method of embodiment 12, wherein the hydrophobic carrier is non-volatile.

[0035] Embodiment 14 is the method of any one of embodiments 12 to 13, wherein the hydrophobic carrier is non-polar.

[0036] Embodiment 15 is the method of any one of embodiments 12 to 14, wherein the hydrophobic carrier comprises a hydrocarbon.

[0037] Embodiment 16 is the method of embodiment 15, wherein the hydrocarbon is petrolatum, mineral oil or paraffin or a mixture thereof.

[0038] Embodiment 17 is the method of embodiment 16, wherein the mineral oil is a heavy mineral oil.

[0039] Embodiment 18 is the method of any one of embodiments 12 to 17, wherein the hydrophobic carrier is greater than 50% by weight of the composition.

[0040] Embodiment 19 is the method of any one of embodiments 12 to 18, wherein the hydrophobic composition comprises one or more than one volatile silicone fluid.

[0041] Embodiment 20 is the method of embodiment 19, wherein the concentration of the one or more volatile silicone fluids is from 5% to 24% by weight of the composition.

[0042] Embodiment 21 is the method of embodiment 20, wherein the volatile silicone fluid is cyclomethicone.

[0043] Embodiment 22 is the method of embodiment 21, wherein the cyclomethicone is cyclopentasiloxane.

[0044] Embodiment 23 is the method of any one of embodiments 1 to 22, wherein the composition is a semisolid composition.

[0045] Embodiment 24 is the method of embodiment 23, wherein the semisolid composition is an ointment.

[0046] Embodiment 25 is the method of any one of embodiments 1 to 24, wherein the composition does not contain volatile C 1 To C 4 Fatty alcohol.

[0047] Embodiment 26 is the method of any one of embodiments 1 to 25, wherein the composition does not comprise an additional penetration enhancer.

[0048] Embodiment 27 is the method of any one of embodiments 1 to 26, wherein the composition does not comprise additional volatile solvents.

[0049] Embodiment 28 is the method of any one of embodiments 1 to 27, wherein the composition does not comprise a surfactant.

[0050] Embodiment 29 is the method of any one of embodiments 1 to 28, wherein the composition does not comprise protein or albumin.

[0051] Embodiment 30 is the method of any one of embodiments 1 to 29, wherein the skin malignancy is skin cancer.

[0052] Embodiment 31 is the method of embodiment 30, wherein the skin cancer is melanoma, basal cell carcinoma, squamous cell carcinoma, or Kaposi's sarcoma.

[0053] Embodiment 32 is the method of any one of embodiments 1 to 29, wherein the skin malignancy is a skin metastasis.

[0054] Embodiment 33 is the method of embodiment 32, wherein the skin metastases are from lung cancer, breast cancer, colon cancer, oral cancer, ovarian cancer, kidney cancer, esophageal cancer, gastric cancer, liver cancer and / or Kaposi's sarcoma.

[0055] Embodiment 34 is the method of any one of embodiments 1 to 33, wherein the method does not comprise an additional skin directed therapy.

[0056] Embodiment 35 is a method of enhancing penetration of taxane nanoparticles into a skin malignancy in a subject, the method comprising topically applying to the affected area a hydrophobic composition comprising a continuous hydrophobic carrier, one or more volatile silicone fluids, and a plurality of taxane nanoparticles.

[0057] Embodiment 36 is the method of embodiment 35, wherein the taxane nanoparticles are suspended in the hydrophobic composition.

[0058] Embodiment 37 is the method of any one of embodiments 35 to 36, wherein the taxane nanoparticles have an average particle size (number average) of 0.1 microns to 1.5 microns.

[0059] Embodiment 38 is the method of any one of embodiments 35 to 37, wherein the taxane nanoparticles are paclitaxel nanoparticles, docetaxel nanoparticles, or cabazitaxel nanoparticles.

[0060] Embodiment 39 is the method of embodiment 38, wherein the taxane nanoparticles are paclitaxel nanoparticles.

[0061] Embodiment 40 is the method of embodiment 39, wherein the paclitaxel nanoparticles have at least 18 m 2 / g specific surface area (SSA).

[0062] Embodiment 41 is the method of embodiment 40, wherein the paclitaxel nanoparticles have 18 m 2 / g to 40m 2 / g specific surface area (SSA).

[0063] Embodiment 42 is the method of any one of embodiments 39 to 42, wherein the concentration of paclitaxel nanoparticles is about 0.15 wt % to about 2 wt %, or 0.1 wt % to 5 wt %.

[0064] Embodiment 43 is the method of any one of embodiments 35 to 42, wherein the composition is anhydrous.

[0065] Embodiment 44 is the method of any one of embodiments 35 to 43, wherein the hydrophobic carrier is non-volatile.

[0066] Embodiment 45 is the method of any one of embodiments 35 to 44, wherein the hydrophobic carrier is non-polar.

[0067] Embodiment 46 is the method of any one of embodiments 35 to 45, wherein the hydrophobic carrier comprises a hydrocarbon.

[0068] Embodiment 47 is the method of embodiment 46, wherein the hydrocarbon is petrolatum, mineral oil or paraffin or a mixture thereof.

[0069] Embodiment 48 is the method of embodiment 47, wherein the mineral oil is a heavy mineral oil.

[0070] Embodiment 49 is the method of any one of embodiments 35 to 48, wherein the hydrophobic carrier is greater than 50% by weight of the composition.

[0071] Embodiment 50 is the method of any one of embodiments 35 to 49, wherein the concentration of the one or more than one volatile silicone fluid is from 5% to 24% by weight of the composition.

[0072] Embodiment 51 is the method of embodiment 50, wherein the volatile silicone fluid is cyclomethicone.

[0073] Embodiment 52 is the method of embodiment 51, wherein the cyclomethicone is cyclopentasiloxane.

[0074] Embodiment 53 is the method of any one of embodiments 35 to 52, wherein the composition is a semisolid composition.

[0075] Embodiment 54 is the method of embodiment 53, wherein the semisolid composition is an ointment.

[0076] Embodiment 55 is the method of any one of embodiments 53 to 54, wherein the viscosity of the composition is 25,000 cp to 500,000 cp, as measured using a Brookfield RV viscometer on a lift stand with a TE spindle at 10 RPM and room temperature for 45 seconds.

[0077] Embodiment 56 is the method of any one of embodiments 35 to 55, wherein the composition does not contain volatile C 1 To C 4 Fatty alcohol.

[0078] Embodiment 57 is the method of any one of embodiments 35 to 56, wherein the composition does not comprise an additional penetration enhancer.

[0079] Embodiment 58 is the method of any one of embodiments 35 to 57, wherein the composition does not comprise additional volatile solvents.

[0080] Embodiment 59 is the method of any one of embodiments 35 to 58, wherein the composition does not comprise a surfactant.

[0081] Embodiment 60 is the method of any one of embodiments 35 to 59, wherein the composition does not comprise protein or albumin.

[0082] Embodiment 61 is the method of any one of embodiments 35 to 60, wherein the skin malignancy is skin cancer.

[0083] Embodiment 62 is the method of embodiment 61, wherein the skin cancer is selected from melanoma, basal cell carcinoma, and squamous cell carcinoma.

[0084] Embodiment 63 is the method of any one of embodiments 35 to 60, wherein the skin malignancy is a skin metastasis.

[0085] Embodiment 64 is the method of embodiment 63, wherein the skin metastases are from lung cancer, breast cancer, colon cancer, oral cancer, ovarian cancer, kidney cancer, esophageal cancer, gastric cancer, liver cancer and / or Kaposi's sarcoma.

[0086] Embodiment 65 is the method of any one of embodiments 35 to 64, wherein the penetration of the taxane nanoparticles from the hydrophobic composition into the skin malignancy is greater than the penetration of the taxane nanoparticles from a topically applied hydrophobic composition comprising a plurality of taxane-based nanoparticles but not comprising one or more than one volatile silicone fluid into the skin malignancy.

[0087] Embodiment 66 is a method of enhancing penetration of taxane nanoparticles into a skin malignancy in a subject, the method comprising topically applying a hydrophobic composition comprising a plurality of taxane nanoparticles to an affected area, wherein penetration of the taxane nanoparticles from the hydrophobic composition into the skin malignancy is greater than penetration of the taxane nanoparticles from the topically applied aqueous composition comprising a plurality of taxane nanoparticles into the skin malignancy.

[0088] Embodiment 67 is the method of embodiment 66, wherein the taxane nanoparticles have an average particle size (number average) of 0.1 microns to 1.5 microns.

[0089] Embodiment 68 is the method of any one of embodiments 66 to 67, wherein the taxane nanoparticles are paclitaxel nanoparticles, docetaxel nanoparticles, or cabazitaxel nanoparticles.

[0090] Embodiment 69 is the method of any one of embodiments 66 to 68, wherein the hydrophobic composition further comprises a hydrophobic carrier.

[0091] Embodiment 70 is the method of any one of embodiments 66 to 69, wherein the skin malignancy is skin cancer or a skin metastasis.

[0092] Embodiment 71 is the method of any one of embodiments 66 to 70, wherein the hydrophobic composition comprises a continuous hydrophobic phase having a plurality of taxane nanoparticles suspended therein.

[0093] The terms "nanoparticle" and "nanoparticle" used herein with respect to taxane particles refer to the average particle size (based on the differential distribution of the number average weight, referred to as "number average") of the taxane particles, which is 0.01 micrometers to 1.5 micrometers (10 nm to 1500 nm) or preferably 0.1 micrometers to 1.5 micrometers (100 nm to 1500 nm).

[0094] As used herein, the term "water-soluble" describes a compound that has a solubility in water of greater than 10 mg / mL or more at room temperature.

[0095] As used herein, the term "poorly water soluble" describes a compound that has a solubility in water of less than or equal to 10 mg / mL at room temperature.

[0096] As used herein, the term "hydrophobic" describes a compound, composition, or carrier that has a solubility in water of less than or equal to 10 mg / mL at room temperature.

[0097] As used herein, the term "volatile" describes a compound, composition, or carrier that has a vapor pressure greater than or equal to 10 Pa at room temperature.

[0098] As used herein, the term "nonvolatile" describes a compound, composition, or carrier that has a vapor pressure of less than 10 Pa at room temperature.

[0099] The term "anhydrous" as used herein with respect to the composition or carrier of the present invention means that less than 3% by weight, preferably less than 2% by weight, more preferably less than 1% by weight, or most preferably 0% by weight of water is present in the composition or carrier. This can be interpreted as the presence of a small amount of water (e.g., water inherently contained in any component of the composition or carrier, water absorbed from the atmosphere, etc.).

[0100] As used herein, the term "skin" refers to the epidermis and / or dermis.

[0101] As used herein, the term "skin malignancy" includes skin cancer and skin metastases.

[0102] An "affected area" of a cutaneous malignancy may include at least a portion of the skin where a cutaneous malignancy lesion (tumor) is evident on the outermost surface of the skin or just below the skin surface (epithelial / dermal overlying), and may include areas of the skin proximal to the cutaneous malignancy that may contain visually undetectable preclinical lesions.

[0103] As used herein, the terms "skin metastases", "skin metastatic lesions", "skin metastatic lesions" or "metastatic disease of the skin" refer to manifestations of malignancies in the skin that are secondary growths (tumors / lesions) arising from primary growths of cancerous tumors elsewhere in the body and may spread from the primary tumor via the lymphatic or blood circulatory systems, or by other means.

[0104] As used herein, the term "skin-directed therapy" refers to electrochemotherapy (ECT), photodynamic therapy (PDT), radiation therapy (RT), intralesional therapy (ILT), or topical therapy.

[0105] As used herein, the term "subject" or "patient" refers to a vertebrate. In some embodiments, the vertebrate can be a mammal. In some embodiments, the mammal can be a primate, including a human.

[0106] As used herein, the term "room temperature" (RT) refers to 20°C to 25°C.

[0107] As used herein, the term "penetration enhancer" or "skin penetration enhancer" refers to a compound or material or substance that aids in the absorption of a drug into the skin (epidermis and dermis).

[0108] As used herein, the term "surfactant" refers to a compound or material or substance that exhibits the ability to reduce the surface tension of water or reduce the interfacial tension between two immiscible substances.

[0109] Unless otherwise indicated, the percentages expressed herein are by weight and are relative to the total weight of the composition.

[0110] The term "about" or "approximately" is defined as close to as understood by those of ordinary skill in the art. In a non-limiting embodiment, the term is defined as within 10%, preferably within 5%, more preferably within 1%, and most preferably within 0.5%.

[0111] For this application, numbers with one or more decimal places may be rounded to the nearest integer using standard rounding guidelines, i.e., if the number being rounded is 5, 6, 7, 8, or 9, it is rounded up; if the number being rounded is 0, 1, 2, 3, or 4, it is rounded down. For example, 3.7 may be rounded to 4.

[0112] The words "comprising," "having," "including," or "containing" are inclusive or open-ended and do not exclude additional, unrecited elements or method steps.

[0113] When used with the terms "comprising," "having," "including," or "containing," the term without a quantifier preceding the element may mean "a," but it also complies with the meaning of "one or more," "at least one," and "one or more than one."

[0114] The compositions and methods of use may "comprise," "consist essentially of," or "consist of" any of the ingredients or steps disclosed throughout this specification. With respect to the phrase "consist essentially of," the fundamental and novel properties of the compositions of the present invention are their ability to topically treat skin malignancies. With respect to the hydrophobic compositions of the present invention, the fundamental and novel properties include the ability to treat skin malignancies and the ability to more effectively penetrate nanoparticles into the epidermis and dermis of the skin, and to be limited to non-transdermal penetration. This eliminates the need for the use of C 1 To C 4 Fatty alcohol or C 1 To C 5 This can be accomplished with fatty alcohols, surfactants and other skin penetration enhancers, and other volatile solvents in addition to volatile silicone fluids (eg, cyclomethicone or cyclopentasiloxane, or combinations thereof).

[0115] When used to modify the phrase "transdermal penetration", "limited", "reduced" or "minimal" means less than 0.01 μg / cm2 when the composition is applied to human cadaver skin. 2 Permeation of drug nanoparticles through human cadaver skin as determined by an in vitro Franz diffusion cell system.

[0116] It is contemplated that any embodiment discussed in this specification can be implemented with respect to any method or composition of the invention, and vice versa.In addition, the compositions of the invention can be used to implement the methods of the invention.

[0117] Other objects, features and advantages of the present invention will become apparent through the following detailed description. However, it should be understood that the detailed description and specific examples, although indicating specific embodiments of the present invention, are given by way of illustration only, because various changes and modifications within the spirit and scope of the present invention will become apparent to those skilled in the art through this detailed description. BRIEF DESCRIPTION OF THE DRAWINGS

[0118] Figure 1 The concentrations of paclitaxel (μg / cm 2 ).

[0119] Figure 2 The concentrations of paclitaxel (μg / cm2) delivered into the epidermis in vitro for formulation F6* (analyzed in duplicate) and formulations F8 to F13 are shown graphically. 2 ).

[0120] Figure 3 The concentrations of paclitaxel (μg / cm2) delivered into the dermis in vitro for formulations F1 to F7 are shown graphically. 2 ).

[0121] Figure 4 The concentrations of paclitaxel (μg / cm2) delivered into the dermis in vitro for formulation F6* (analyzed in duplicate) and formulations F8 to F13 are shown graphically. 2 ).

[0122] Figure 5 is a photograph of skin metastatic lesions on the breast of a woman with stage 4 breast cancer at baseline (Day 1).

[0123] Figure 6 This is a photograph of skin metastases on the breast of a woman with stage 4 breast cancer on day 8 after local treatment.

[0124] Figure 7 This is a photograph of skin metastases on the breast of a woman with stage 4 breast cancer 15 days after local treatment.

[0125] Figure 8 is a photograph of skin metastases on the breast of a woman with stage 4 breast cancer at day 29 after local treatment. DETAILED DESCRIPTION

[0126] In some aspects, the present invention relates to a method of treating a patient's skin malignancies (including skin cancer and skin metastases) by topically applying a composition comprising a taxane to the affected area (topical therapy). In some embodiments, the taxane is paclitaxel. In other embodiments, the taxane is docetaxel or cabazitaxel. In other embodiments, a combination of taxanes (e.g., paclitaxel and docetaxel, or paclitaxel and cabazitaxel, or docetaxel and cabazitaxel, or paclitaxel, docetaxel and cabazitaxel) may be used. In some embodiments, the composition comprises a carrier. In some embodiments, the carrier is anhydrous and / or hydrophobic. In other aspects, the carrier is aqueous. In some embodiments, the taxane is a plurality of taxane nanoparticles. In some embodiments, the taxane is dissolved. Suitable compositions for use in the methods of the present invention are disclosed in International Patent Publication WO 2017 / 049083 (Application No. PCT / US2016 / 052133), which is incorporated herein by reference. In a preferred embodiment, the composition is a hydrophobic composition comprising a continuous hydrophobic carrier, one or more than one volatile silicone fluid, and a plurality of taxane nanoparticles, wherein the taxane nanoparticles are suspended in the composition, and wherein the average particle size (number average) of the taxane nanoparticles is 0.1 microns to 1.5 microns. In some embodiments, the concentration of the one or more than one volatile silicone fluid is 5 wt % to 24 wt %. In some embodiments, the composition does not comprise a volatile C 1 To C 4 Fatty alcohol or C 1 To C 5Fatty alcohol. In some embodiments, the concentration of the taxane nanoparticles is a concentration effective to provide improved treatment of skin malignancies. In some embodiments, the concentration of the taxane nanoparticles is about 0.1 wt % to about 2 wt %, or about 0.15 wt % to about 2 wt %, or 0.1 wt % to 5 wt %. In some embodiments, the method does not include additional skin-directed therapy, such as electrochemotherapy (ECT), photodynamic therapy (PDT), radiation therapy (RT), or intralesional therapy (ILT).

[0127] In some embodiments, the skin metastases are from one or more of the following cancers: breast cancer, lung cancer, paranasal sinus cancer, laryngeal cancer, oral cancer, colorectal cancer, stomach cancer, ovarian cancer, testicular cancer, bladder cancer, prostate cancer, cervical cancer, vaginal cancer, thyroid cancer, endometrial cancer, kidney cancer, esophageal cancer, pancreatic cancer, liver cancer, melanoma, and Kaposi's sarcoma (including Kaposi's sarcoma associated with AIDS). In some embodiments, the skin cancer is melanoma, basal cell carcinoma, and / or squamous cell carcinoma.

[0128] I. Composition

[0129] In one aspect of the invention, the composition of the invention is hydrophobic and comprises a continuous hydrophobic carrier, one or more than one volatile silicone fluid (e.g., cyclomethicone) and a plurality of taxane nanoparticles. The composition may be a suspension of a plurality of taxane nanoparticles in a mixture of a hydrophobic carrier and a volatile silicone fluid. The taxane nanoparticles may be completely dispersed in, or partially dispersed in and partially dissolved in the composition. In various embodiments, the taxane nanoparticles are not completely dissolved in the composition. The hydrophobic composition may be anhydrous. A hydrophobic composition is a composition in which the total amount of hydrophobic components in the composition is greater than the total amount of non-hydrophobic components in the composition. The hydrophobic carrier may be the continuous phase of the hydrophobic composition. Thus, the composition of the invention may comprise at least two phases: a continuous hydrophobic carrier phase and a suspended taxane nanoparticle phase. The volatile silicone fluid may be dissolved in the continuous phase and / or dispersed in the continuous phase.

[0130] Surprisingly, the hydrophobic compositions of the present invention comprising low concentrations (less than 25 wt%) of volatile silicone fluids and a continuous anhydrous hydrophobic carrier exhibited greater skin penetration (i.e., penetration into the epidermal and / or dermal portions of the skin) of the taxane nanoparticles compared to the skin penetration of the taxane nanoparticles from the hydrophobic carrier alone. In fact, even more surprisingly, the addition of other skin penetration enhancers had little or no effect on the skin penetration of these compositions. Notably, however, the taxane nanoparticles did not penetrate through the skin (i.e., percutaneously), or only penetrated through the skin in negligible amounts, i.e., less than 0.01 μg / cm 2. In addition, the skin penetration (i.e., dermal or epidermal penetration) of the taxane nanoparticles from the anhydrous hydrophobic composition is much better than the skin penetration of the taxane nanoparticles from the aqueous composition, even if the aqueous composition contains a skin penetration enhancer. In addition, surprisingly, the hydrophobic composition of the present invention comprising less than 25% of a volatile silicone fluid and a hydrophobic carrier does not need to contain alcohol, additional volatile solvents, additional penetration enhancers or surfactants to provide enhanced skin penetration, thereby allowing the most cost-effective and simplified composition to be obtained, which can reduce skin irritation when the composition is topically applied. However, if desired, these components can be included in the composition of the present invention. In some embodiments, the hydrophobic composition does not / does not contain an additional penetration enhancer. In some embodiments, the hydrophobic composition does not / does not contain laurocapram. In some embodiments, the hydrophobic composition does not / does not contain diethylene glycol monoethyl ether (DGME). In some embodiments, the hydrophobic composition does not / does not contain isopropyl myristate. In some embodiments, the hydrophobic composition does not / does not contain α-tocopherol. In some embodiments, the hydrophobic composition is free of / does not contain additional volatile solvents or compounds. In some embodiments, the hydrophobic composition is free of / does not contain any alcohol or C 1 To C 4 In some embodiments, the hydrophobic composition does not contain alcohol or C 1 To C 5 Fatty alcohol. In other embodiments, the hydrophobic composition is free of / does not contain a surfactant. In other embodiments, the hydrophobic composition is free of / does not contain a polymer / copolymer (or a biodegradable polymer / copolymer). In other embodiments, the hydrophobic composition is free of / does not contain poloxamers, styrene-isobutylene-styrene (SIBS), polyanhydride copolymers, polycaprolactone, polyethylene glycol, poly(bis(p-carboxyphenoxy)propane-sebacic acid and / or poly(D,L-lactic acid-co-glycolic acid) (PLGA). In various embodiments, the volatile silicone fluid is cyclomethicone. In other embodiments, the cyclomethicone is cyclopentasiloxane. In some embodiments, the hydrophobic composition is a semisolid composition. In other embodiments, the hydrophobic composition is an ointment. In some embodiments, the hydrophobic composition is not a spray and is not sprayable.

[0131] In some embodiments, the hydrophobic composition is a semisolid composition, including an ointment, and has a viscosity of 12500 cp to 247500 cp, or 25000 cp to 150000 cp, measured at room temperature using a Brookfield RV viscometer with a small sample adapter with an SC4-14 spindle and a 6R chamber at 5 rpm and a 2-minute equilibrium time. An alternative method for measuring the viscosity of a hydrophobic semisolid composition is to use a Brookfield RV viscometer on a lifting stand with a TE spindle connected at 10 RPM, room temperature for 45 seconds. In some embodiments, the hydrophobic composition is a semisolid composition, including an ointment, and has a viscosity of 25,000 cp to 500,000 cp, or 25,000 cp to 400,000 cp, or 25,000 cp to 350,000 cp, or 25,000 cp to 300,000 cp, or 50,000 cp to 500,000 cp, or 50,000 cp to 400,000 cp, or 50,000 cp to 350,000 cp, 50,000 cp to 30,000 cp. 0cp, or 75000cp to 500000cp, or 75000cp to 400000cp, or 75000cp to 350000cp, or 75000cp to 300000cp, or 100000cp to 500000cp, or 100000cp to 400000cp, or 100000cp to 350000cp, or 100000cp to 300000cp, the viscosity being measured using a Brookfield RV viscometer on a lifting stand connected to a TE spindle at 10RPM, room temperature for 45 seconds.

[0132] In another aspect, the present invention relates to a composition for inhibiting crystal growth of taxane nanoparticles in a carrier. In some embodiments, inhibiting crystal growth of taxane nanoparticles in a carrier is achieved by including the nanoparticles in a hydrophobic carrier. In some embodiments, the hydrophobic carrier comprises a hydrocarbon. In some embodiments, the hydrophobic carrier comprises petrolatum, mineral oil and / or paraffin. In some embodiments, the mineral oil is a heavy mineral oil. In other embodiments, the hydrophobic carrier further comprises one or more than one volatile silicone fluid. In other embodiments, the volatile silicone fluid is cyclomethicone. In other embodiments, the cyclomethicone is cyclopentasiloxane. In other embodiments, inhibiting crystal growth of taxane nanoparticles in an aqueous carrier is achieved by including the nanoparticles in an aqueous carrier comprising poloxamer 407, a quaternary ammonium compound, or a cross-linked acrylic polymer or a mixture thereof.

[0133] The composition of the present invention can be formulated into various forms suitable for drug delivery and topical delivery. Non-limiting examples include semisolid compositions, lotions, suspensions, emulsions, creams, gels, ointments, pastes, aerosol sprays, aerosol foams, non-aerosol sprays, non-aerosol foams, films and tablets. Semisolid compositions include ointments, pastes and creams. For purposes of the present invention, semisolid compositions are non-sprayable. Compositions can be impregnated in gauze, bandages or other skin dressing materials. In some embodiments, compositions are semisolid compositions. In some embodiments, compositions are ointments. In some embodiments, compositions are gels. In some embodiments, compositions are suspensions. In some embodiments, compositions are not sprays and are non-sprayable.

[0134] The compositions of the present invention can be packaged in any packaging structure suitable for topical products. Non-limiting examples include bottles, bottles with pumps, inverted bottles, tubes (aluminum tubes, plastic tubes or laminated tubes), wide-mouth bottles, non-aerosol pump sprayers, aerosol containers, pouches and packets. The packaging can be configured for single-dose or multi-dose administration.

[0135] In various embodiments, the compositions of the present invention are hydrophobic. In other embodiments, the hydrophobic compositions are anhydrous. In various embodiments, the hydrophobic carrier is non-polar and / or non-volatile. In other embodiments, the composition is aqueous. In other embodiments, the compositions of the present invention are sterile. In other embodiments, the hydrophobic compositions are non-sterile. In other embodiments, the hydrophobic compositions have a low bioburden. In various embodiments, the hydrophobic compositions of the present invention do not contain additional skin penetration enhancers. In other embodiments, the hydrophobic compositions do not contain additional volatile solvents. In other embodiments, the hydrophobic compositions of the present invention do not contain surfactants. In other embodiments, the hydrophobic compositions do not contain alcohols, C 1 To C 4 Fatty alcohol or C 1 To C 5 Fatty alcohol.

[0136] A. Taxane Nanoparticles

[0137] Taxanes are poorly water-soluble drugs, with a solubility in water of less than or equal to 10 mg / mL at room temperature. Taxanes are widely used as chemotherapeutic agents. As used herein, the term "taxane" includes paclitaxel (I), docetaxel (II), cabazitaxel (III) and / or any other taxane derivatives.

[0138]

[0139] The taxane nanoparticles can be paclitaxel nanoparticles, docetaxel nanoparticles, or nanoparticles of cabazitaxel nanoparticles or other taxane derivatives. Paclitaxel and docetaxel active pharmaceutical ingredients (API) can be commercially obtained from Phyton Biotech LLC, Vancouver, Canada. Docetaxel API and nanoparticles contain no less than 90%, or no less than 95%, or no less than 97.5% of docetaxel calculated on an anhydrous, solvent-free base. Paclitaxel API and nanoparticles contain no less than 90%, or no less than 95%, or no less than 97% of paclitaxel calculated on an anhydrous, solvent-free base. Paclitaxel API and nanoparticles can be prepared by semi-synthetic chemical processes or natural sources (e.g., plant cell fermentation or extraction). Paclitaxel is sometimes also referred to as TAXOL by the trade name, although it is a misnomer because TAXOL is the trade name for a solution of paclitaxel in polyoxyethylated castor oil and ethanol that is diluted with a suitable parenteral fluid before intravenous infusion. Paclitaxel is a poorly water-soluble drug. The solubility of paclitaxel in water is less than 0.05 ppm, as determined experimentally by the solubility method described in Example 1. The taxane nanoparticles may be in crystalline form or amorphous form or a combination of both.

[0140] In various embodiments of the present invention, the taxane or paclitaxel nanoparticles are uncoated (original) individual particles; the taxane or paclitaxel nanoparticles are not bound to any substance; no substance is adsorbed on the surface of the taxane or paclitaxel nanoparticles; the taxane or paclitaxel nanoparticles are not encapsulated in any substance; the taxane or paclitaxel nanoparticles are not coated with any substance; the taxane or paclitaxel nanoparticles are not microemulsions, nanoemulsions, microspheres or liposomes of taxane or paclitaxel; the taxane or paclitaxel particles are not bound to monomers, polymers or In some embodiments, the composition does not contain a polymer or a biocompatible polymer. In some embodiments, the composition does not contain a protein. In some aspects of the present invention, the composition does not contain albumin. In some aspects of the present invention, the composition does not contain hyaluronic acid. In some aspects of the present invention, the composition does not contain a conjugate of hyaluronic acid and taxane. In some aspects of the present invention, the composition does not contain a conjugate of hyaluronic acid and paclitaxel. In some aspects of the invention, the composition is free of / does not comprise poloxamer, styrene-isobutylene-styrene (SIBS), polyanhydride copolymers, polycaprolactone, polyethylene glycol, poly(bis(p-carboxyphenoxy)propane-sebacic acid and / or poly(D,L-lactic acid-co-glycolic acid (PLGA).

[0141] The taxane nanoparticles including paclitaxel nanoparticles, docetaxel nanoparticles or cabazitaxel nanoparticles may have a particle size of 0.01 micron to 1.5 micron, or 0.01 micron to 1.2 micron, or 0.01 micron to 1 micron, or 0.01 micron to less than 1 micron, or 0.01 micron to 0.9 micron, or 0.01 micron to 0.8 micron, or 0.01 micron to 0.7 micron, or 0.1 micron to 1.5 micron, or 0.1 micron to 1.2 micron, or 0.1 micron to 1 micrometer, or 0.1 micrometer to less than 1 micrometer, or 0.1 micrometer to 0.9 micrometer, or 0.1 micrometer to 0.8 micrometer, or 0.1 to 0.7 micrometer, or 0.2 micrometer to 1.5 micrometer, or 0.2 micrometer to 1.2 micrometer, or 0.2 micrometer to 1 micrometer, or 0.2 micrometer to less than 1 micrometer, or 0.2 micrometer to 0.9 micrometer, or 0.2 micrometer to 0.8 micrometer, or 0.2 micrometer to 0.7 micrometer, or 0.3 micrometer to 1.5 micrometer, or 0.3 micrometer to 1.2 micrometer, or 0.3 micron to 1 micron, or 0.3 micron to less than 1 micron, or 0.3 micron to 0.9 micron, or 0.3 micron to 0.8 micron, or 0.3 micron to 0.7 micron, or 0.4 micron to 1.5 micron, or 0.4 micron to 1.2 micron, or 0.4 micron to 1 micron, or 0.4 micron to less than 1 micron, or 0.4 micron to 0.9 micron, or 0.4 micron to 0.8 micron, or 0.4 micron to 0.7 micron, or 0.5 micron to 1.5 micron, or 0.5 micron The average particle size (number average) is from 0.5 micrometers to 1.2 micrometers, or from 0.5 micrometers to 1 micrometer, or from 0.5 micrometers to less than 1 micrometer, or from 0.5 micrometers to 0.9 micrometers, or from 0.5 micrometers to 0.8 micrometers, or from 0.5 micrometers to 0.7 micrometers, or from 0.6 micrometers to 1.5 micrometers, or from 0.6 micrometers to 1.2 micrometers, or from 0.6 micrometers to 1 micrometer, or from 0.6 micrometers to less than 1 micrometer, or from 0.6 micrometers to 0.9 micrometers, or from 0.6 micrometers to 0.8 micrometers, or from 0.6 micrometers to 0.7 micrometers.

[0142] When included in the composition, the particle size of the taxane is determined by a particle size analyzer, and the measurement is expressed as the mean diameter based on the number average distribution. A suitable particle size analyzer is an instrument that employs light obscuration, also known as light zone or single particle optical sensing (SPOS) analysis technology. A suitable light obscuration particle size analyzer is the ACCUSIZER, which is available from Particle Sizing Systems, Port Richey, Florida.

[0143] In various embodiments, when the composition is stored at room temperature for at least 1 month, or at least 3 months, or at least 6 months, or at least 12 months, the average particle size of the taxane nanoparticles contained in the composition does not grow by more than 20% of the initial average particle size. As used herein with respect to the particle size of the taxane nanoparticles, the term "initial average particle size" is the average particle size of the taxane contained in the composition when measured by a particle size analyzer within 45 days after the manufacture of the composition is completed (manufacturing date), and the initial average particle size is 0.1 μm to 1.5 μm (number average) or 0.01 μm to 1.5 μm (number average).

[0144] Nanoparticles of taxanes can be made using various methods and equipment for reducing particle size known in the art. These methods include, but are not limited to, wet or dry milling, micronization, disintegration, pulverization, and supercritical carbon dioxide particle size reduction methods. In various embodiments, the taxane or paclitaxel nanoparticles are made by a supercritical carbon dioxide particle size reduction method (also known as "precipitation with compressed antisolvent" or "PCA"), as disclosed in US Patents: US 5874029, US 5833891, US 6113795, US7744923, US 8778181, US Publication 2014 / 0296140, US Publication 2016 / 0354336, US Publication 2016 / 0374953, and International Patent Application Publication WO 2016 / 197091 (Application No. PCT / US16 / 35993), all of which are incorporated herein by reference.

[0145] In the supercritical carbon dioxide particle size reduction process, supercritical carbon dioxide (antisolvent) and solvents such as acetone or ethanol are used to generate uncoated taxane nanoparticles within a well-characterized particle size distribution. The carbon dioxide and acetone (up to 0.5% residual solvent may remain) are removed during processing, leaving behind a powder of taxane nanoparticles with a size typically ranging from about 200 nm to about 800 nm. Stability studies have shown that the powder in bottle dosage form is stable when stored at controlled room temperature (25°C / 60% relative humidity) for up to 59 months and under accelerated conditions (40°C / 75% relative humidity) for up to 6 months.

[0146] Compared to taxane nanoparticles prepared by conventional particle size reduction methods using physical impact or grinding (e.g., wet or dry grinding, micronization, disintegration, pulverization, microfluidization, or pulverization), taxane nanoparticles prepared by various supercritical carbon dioxide particle size reduction methods can have unique physical characteristics. As disclosed in US Publication No. 2016 / 0354336 and International Patent Application Publication No. WO 2016 / 197091 (all of which are incorporated herein by reference), these unique characteristics include 0.05 g / cm 3 Up to 0.15g / cm3 Bulk density (not tap density) and at least 18m 2 The specific surface area (SSA) of taxane (paclitaxel and docetaxel) nanoparticles of 100 g / g, prepared by the supercritical carbon dioxide particle size reduction method described in US Publication No. 2016 / 0354336 and International Patent Application Publication No. WO 2016 / 197091, as described below. The bulk density is generally lower than the bulk density of taxane particles prepared by conventional methods, and the SSA is generally higher than the SSA of taxane particles prepared by conventional methods. These unique characteristics result in a significant increase in the dissolution rate in water / methanol media compared to taxanes prepared by conventional methods. As used herein, "specific surface area (SSA)" is the total surface area of ​​taxane nanoparticles per unit mass of taxane measured by the adsorption specific surface ("BET") isotherm by the following method: 200 mg to 300 mg of a known mass of analyte is added to a 30 mL sample tube. The loaded tube is then mounted on a BET-202A model Porous Materials Inc. Then use The software package performs the test automatically and then calculates the surface area of ​​each sample. Bulk density measurements can be performed by pouring the taxane nanoparticles into a graduated cylinder at room temperature without tapping, measuring the mass and volume, and calculating the bulk density.

[0147] As disclosed in US Publication No. 2016 / 0354336 and International Patent Application Publication No. WO 2016 / 197091, it was shown that the SSA of paclitaxel nanoparticles prepared by grinding paclitaxel in a Deco-PBM-V-0.41 ball mill at 5 mm ball size at 600 RPM for 60 minutes at room temperature was 15.0 m 2 / g, bulk density is 0.31g / cm 3 It is also disclosed in US Publication No. 2016 / 0354336 and International Patent Application Publication No. WO 2016 / 197091 that many paclitaxel nanoparticles have an SSA of 37.7 m when prepared by a supercritical carbon dioxide process using the following method: 2 / g, bulk density is 0.085g / cm 3 : Prepare a 65 mg / ml paclitaxel solution in acetone. A spray nozzle (BETE Fog Nozzle, Inc.) and an acoustic probe (Qsonica, model number Q700) were placed in the crystallization chamber, about 8 mm apart. A stainless steel mesh filter with about 100 nm pores was connected to the crystallization chamber to collect the precipitated paclitaxel nanoparticles. Supercritical carbon dioxide was placed in the crystallization chamber of the manufacturing equipment and reached about 1200 psi at about 38 ° C and a flow rate of 24 kg / hour. At a frequency of 20 kHz, the acoustic probe was adjusted to 60% of the total output power. An acetone solution containing paclitaxel was pumped through the nozzle at a flow rate of 4.5 mL / minute for about 36 hours. The SSA value of many other paclitaxel nanoparticles prepared by the above-mentioned supercritical carbon dioxide method is: 22.27 m 2 / g, 23.90m 2 / g, 26.19m 2 / g, 30.02m 2 / g, 31.16m 2 / g, 31.70m 2 / g, 32.59m 2 / g, 33.82m 2 / g, 35.90m 2 / g, 38.22m 2 / g and 38.52m 2 / g.

[0148] As disclosed in US Publication No. 2016 / 0354336 and International Patent Application Publication No. WO 2016 / 197091, studies have shown that the SSA of docetaxel nanoparticles prepared by grinding docetaxel in a Deco-PBM-V-0.41 ball mill with a 5 mm ball size at 600 RPM for 60 minutes at room temperature was 15.2 m 2 / g, bulk density is 0.44g / cm 3 It is also disclosed in US Publication No. 2016 / 0354336 and International Patent Application Publication No. WO 2016 / 197091 that the SSA of docetaxel nanoparticles is 44.2 m when prepared by a supercritical carbon dioxide method using the following method: 2 / g, bulk density is 0.079g / cm 3: A 79.32 mg / ml docetaxel solution was prepared in ethanol. The nozzle and the sonic probe were placed in a pressurizable chamber, about 9 mm apart. A stainless steel mesh filter with about 100 nm pores was connected to the pressurizable chamber to collect the precipitated docetaxel nanoparticles. Supercritical carbon dioxide was placed in a pressurizable chamber of the manufacturing equipment and reached about 1200 psi at a flow rate of about 38 ° C and 68 slpm. At a frequency of 20 kHz, the sonic probe was adjusted to 60% of the total output power. The ethanol solution containing docetaxel was pumped through the nozzle at a flow rate of 2 mL / min for about 95 minutes. Then, when the mixture was pumped through the stainless steel mesh filter, the precipitated docetaxel agglomerates and particles were collected from the supercritical carbon dioxide. The filter containing the docetaxel nanoparticles was opened and the resulting product was collected from the filter.

[0149] As disclosed in US Publication 2016 / 0354336 and International Patent Application Publication WO 2016 / 197091, dissolution studies have shown that the dissolution rate of paclitaxel and docetaxel nanoparticles prepared by the supercritical carbon dioxide method described in US Publication 2016 / 0354336 and International Patent Application Publication WO 2016 / 197091 in methanol / water media is increased compared to paclitaxel and docetaxel nanoparticles prepared by grinding paclitaxel and docetaxel using a Deco-PBM-V-0.41 ball mill with a ball size of 5 mm at 600 RPM, room temperature for 60 minutes. The steps for determining the dissolution rate are as follows. For paclitaxel, about 50 mg of the material was coated on about 1.5 grams of 1 mm glass beads by rolling the material and beads in a vial for about 1 hour. The beads were transferred to a stainless steel mesh container and placed in a dissolution bath containing a methanol / water 50 / 50 (vol / vol) medium at 37°C, pH 7, USP Apparatus II (paddle type), operated at 75 rpm. At 10 minutes, 20 minutes, 30 minutes, 60 minutes and 90 minutes, 5 mL aliquots were taken, filtered through a 0.22 μm filter, and analyzed at 227 nm on a UV / VIS spectrophotometer. The absorbance values ​​of the samples were compared with the absorbance values ​​of standard solutions prepared in the dissolution medium to determine the amount of dissolved material. For docetaxel, approximately 50 mg of material was placed directly into a dissolution bath containing a methanol / water 15 / 85 (vol / vol) medium at 37°C, pH 7, USP Apparatus II (paddle type), operated at 75 rpm. At 5 minutes, 15 minutes, 30 minutes, 60 minutes, 120 minutes and 225 minutes, 5 mL aliquots were taken out, filtered through a 0.22 μm filter, and analyzed on a UV / VIS spectrophotometer at 232 nm. The absorbance values ​​of the samples were compared with the absorbance values ​​of the standard solutions prepared in the dissolution medium to determine the amount of dissolved material. For paclitaxel, the solubility of the nanoparticles prepared by the supercritical carbon dioxide method was 47% within 30 minutes, while the solubility of the nanoparticles prepared by grinding was 32% within 30 minutes. For docetaxel, the solubility of the nanoparticles prepared by the supercritical carbon dioxide method was 27% within 30 minutes, while the solubility of the nanoparticles prepared by grinding was 9% within 30 minutes.

[0150] In some embodiments, the SSA of the paclitaxel nanoparticles is at least 18 m 2 / g, at least 19m 2 / g, at least 20m 2 / g, at least 21m 2 / g, at least 22m 2 / g, at least 23m2 / g, at least 24m 2 / g, at least 25m 2 / g, at least 26m 2 / g, at least 27m 2 / g, at least 28m 2 / g, at least 29m 2 / g, at least 30m 2 / g, at least 31m 2 / g, at least 32m 2 / g, at least 33m 2 / g, at least 34m 2 / g or at least 35m 2 In other embodiments, the SSA of the paclitaxel nanoparticles is 18 m 2 / g to 50m 2 / g, or 20m 2 / g to 50m 2 / g, or 22m 2 / g to 50m 2 / g, or 25m 2 / g to 50m 2 / g, or 30m 2 / g to 50m 2 / g, or 18m 2 / g to 45m 2 / g, or 20m 2 / g to 45m 2 / g, or 22m 2 / g to 45m 2 / g, or 25m 2 / g to 45m 2 / g, or 30m 2 / g to 45m 2 / g, or 18m 2 / g to 40m 2 / g, or 20m 2 / g to 40m 2 / g, or 22m 2 / g to 40m 2 / g, or 25m 2 / g to 40m 2 / g, or 30m 2 / g to 40m 2 / g.

[0151] In some embodiments, the bulk density (non-tapped density) of the paclitaxel nanoparticles is 0.05 g / cm 3 Up to 0.15g / cm 3 or 0.05g / cm 3 Up to 0.20g / cm3 .

[0152] In some embodiments, the paclitaxel nanoparticles have a solubility of at least 40 wt % in a 50% methanol / 50% water (v / v) solution in a USPII paddle apparatus operated at 75 RPM, 37° C., and pH 7 in 30 minutes or less.

[0153] In some embodiments, the docetaxel nanoparticles have at least 18 m 2 / g, at least 19m 2 / g, at least 20m 2 / g, at least 21m 2 / g, at least 22m 2 / g, at least 23m 2 / g, at least 24m 2 / g, at least 25m 2 / g, at least 26m 2 / g, at least 27m 2 / g, at least 28m 2 / g, at least 29m 2 / g, at least 30m 2 / g, at least 31m 2 / g, at least 32m 2 / g, at least 33m 2 / g, at least 34m 2 / g, at least 35m 2 / g, at least 36m 2 / g, at least 37m 2 / g, at least 38m 2 / g, at least 39m 2 / g, at least 40m 2 / g, at least 41m 2 / g or at least 42m 2 In other embodiments, the docetaxel nanoparticles have an SSA of 18 m 2 / g to 60m 2 / g, or 22m 2 / g to 60m 2 / g, or 25m 2 / g to 60m 2 / g, or 30m 2 / g to 60m 2 / g, or 40m 2 / g to 60m 2 / g, or 18m 2 / g to 50m 2 / g, or 22m 2 / g to 50m 2 / g, or 25m 2 / g to 50m 2 / g, or 30m 2 / g to 50m 2 / g or 40m 2 / g to 50m 2 / g of SSA.

[0154] In some embodiments, the bulk density (non-tapped density) of docetaxel nanoparticles is 0.05 g / cm 3 Up to 0.15g / cm 3 .

[0155] In some embodiments, the solubility of docetaxel nanoparticles in a solution of 15% methanol / 85% water (v / v) in a USPII paddle apparatus operated at 75 RPM, 37°C, and pH 7 is at least 20 wt % in 30 minutes or less.

[0156] It was found that paclitaxel nanoparticle crystals tend to grow over time in suspensions in water or saline solutions, forming large needle-shaped crystals. Crystal growth studies were performed and the results are shown in Table 2 of Example 2 below. It was found that nanoparticle crystals did not grow in hydrophobic materials. In addition, unexpectedly, nanoparticle crystals did not grow in aqueous solutions of benzalkonium chloride, CARBOPOL ULTREZ10 or poloxamer 407.

[0157] B. Hydrophobic carrier

[0158] The hydrophobic carrier of the present invention may include materials from plants, animals, paraffin and / or synthetic sources. Hydrophobic substances are generally referred to as materials that lack affinity for water and repel water. The hydrophobic carrier may be the continuous phase of the composition. In various embodiments, the hydrophobic carrier is non-polar and / or non-volatile. Non-limiting examples include fats, butters, greases, waxes, solvents and oils; mineral oils; vegetable oils; mineral esters; water-insoluble organic esters and triglycerides; and fluorides. The hydrophobic carrier may also include silicone materials. Silicone materials are defined as compounds based on polydialkylsiloxanes and include polymers, elastomers (cross-linked silicones) and adhesives (branched silicones). Non-limiting examples of silicone materials include dimethicone (polydimethylsiloxane), dimethicone copolyols, cyclomethicone, simethicone, silicone elastomers, such as ST-elastomer 10 (Dow Corning), silicone oils, silicone polymers, volatile silicone fluids and silicone waxes. In some embodiments, the hydrophobic carrier does not comprise a silicone material.

[0159] Materials of vegetable origin include, but are not limited to, peanut oil, Peru balsam oil, carnauba wax, candelilla wax, castor oil, hydrogenated castor oil, cocoa butter, coconut oil, corn oil, cottonseed oil, jojoba oil, macadamia seed oil, olive oil, orange oil, orange wax, palm kernel oil, rapeseed oil, safflower oil, sesame seed oil, shea resin, soybean oil, sunflower seed oil, tea tree oil, vegetable oils, and hydrogenated vegetable oils.

[0160] Non-limiting examples of animal-derived materials include beeswax (yellow wax and white wax), cod liver oil, emu oil, lard, mink oil, shark liver oil, squalane, squalene and tallow. Non-limiting examples of paraffin-based materials include isoparaffin, microcrystalline wax, heavy mineral oil, light mineral oil, ozokerite, mineral esters, white mineral esters and paraffin.

[0161] Non-limiting examples of organic esters and triglycerides include C 12 To C 15 Alkyl benzoates, isopropyl myristate, isopropyl palmitate, medium chain triglycerides, mono- and diglycerides, trilaurin and trihydroxystearin.

[0162] A non-limiting example of a fluorinated compound is perfluoropolyether (PFPE), such as commercially available from Solvay Specialty Polymers.

[0163] The hydrophobic carrier of the present invention may comprise a pharmaceutical grade hydrophobic substance. In various embodiments of the present invention, the hydrophobic carrier comprises petrolatum, mineral oil or paraffin or a mixture thereof. In some embodiments, the mineral oil is heavy mineral oil.

[0164] In some embodiments, the concentration of the hydrophobic carrier in the composition is greater than 10% by weight of the total weight of the composition. In other embodiments, the concentration of the hydrophobic carrier in the composition is greater than 15% by weight, or 20% by weight, or 25% by weight, or 30% by weight, or 35% by weight, or 40% by weight, or 45% by weight, or 50% by weight, or 55% by weight, or 60% by weight, or 65% by weight, or 70% by weight, or 75% by weight, or 80% by weight, or 82% by weight, or 85% by weight, or 87% by weight, or 90% by weight of the total weight of the composition. In other embodiments, the concentration of the hydrophobic carrier in the composition is greater than 10% to 95% by weight of the total weight of the composition. In other embodiments, the concentration of the hydrophobic carrier in the composition is from 11 wt % to 95 wt %, or from 12 wt % to 95 wt %, or from 13 wt % to 95 wt %, or from 14 wt % to 95 wt %, or from 15 wt % to 95 wt %, or from 16 wt % to 95 wt %, or from 17 wt % to 95 wt %, or from 18 wt % to 95 wt %, or from 19 wt % to 95 wt %, or from 20 wt % to 95 wt %, based on the total weight of the composition.

[0165] (i) Mineral esters

[0166] Petrolatum is a purified mixture of semisolid saturated hydrocarbons obtained from petroleum, which varies in color from dark amber to light yellow. White petrolatum is completely or almost decolorized, and the color varies from milky white to snowy white. Petrolatum is available with different melting points, viscosities and consistency characteristics. Petrolatum may also contain stabilizers, such as antioxidants. Pharmaceutical grade petrolatum includes Petrolatum USP and White Petrolatum USP.

[0167] Various mineral esters are commercially available from Penreco under the following trade names: ULTIMA, SUPER, SNOW, REGENT, LILY, CREAM, ROYAL, BLOND, and AMBER. Various grades of mineral esters are also commercially available from Sonneborn under the following trade names: ALBA, SUPER WHITE PROTOPET, SUPER WHITE FONOLINE, WHITE PROTOPET 1S, WHITE PROTOPET 2L, WHITE PROTOPET 3C, WHITE FONOLINE, PERFECTA, YELLOW PROTOPET 2A, YELLOW FONOLINE, PROTOLINE, SONOJELL #4, SONOJELL #9, MINERAL JELLY #10, MINERAL JELLY #14, MINERAL JELLY #17, and CARNATION TROUGH GREASE. Mineral esters are also available from Spectrum Chemical Mfg. Corp.

[0168] (ii) Mineral oil

[0169] Mineral oil is a mixture of liquid hydrocarbons obtained from petroleum. Mineral oil can be obtained in various viscosity grades, such as light mineral oil, heavy mineral oil and extra heavy mineral oil. The kinematic viscosity of light mineral oil at 40°C is not more than 33.5 centistokes. The kinematic viscosity of heavy mineral oil at 40°C is not less than 34.5 centistokes. Mineral oil may contain a suitable stabilizer. Pharmaceutical grade mineral oil includes Mineral Oil USP, which is a heavy mineral oil, and LightMineral Oil NF, which is a light mineral oil. Mineral oil can be commercially available from Penreco under the trade name DRAKEOL, and commercially available from Sonneborn under the trade names BENOL, BLANDOL, BRITOL, CARNATION, ERVOL, GLORIA, KAYDOL, KLEAROL, PROTOL and RUDOL. Mineral oil can also be commercially available from Spectrum Chemical Mfg.Corp.

[0170] (iii) Paraffin

[0171] Paraffin wax is a purified mixture of solid hydrocarbons obtained from petroleum. It can also be synthesized by the Fischer-Tropsch process from carbon monoxide and hydrogen, which are catalytically converted into a mixture of paraffin hydrocarbons. Paraffin wax may contain an antioxidant. Pharmaceutical grade paraffin waxes include Paraffin NF and Synthetic Paraffin NF. Paraffin wax is commercially available from Spectrum Chemical Mfg. Corp, Koster Keunen, Inc, and Frank B. Ross, Inc.

[0172] C. Volatile silicone fluid

[0173] Volatile silicone fluids, also referred to as volatile silicone oils, are volatile liquid polysiloxanes that can be cyclic or linear. They are liquid at room temperature. Volatile silicone fluids are hydrophobic materials. Linear volatile silicone fluids include polydimethylsiloxane, hexamethyldisiloxane, and octamethyltrisiloxane, which are commercially available from DowCorning under the trade names DOW CORNING Q7-9180 Silicone Fluid 0.65 cSt and DOW CORNING Q7-9180 Silicone Fluid 1.0 cSt, respectively. Cyclic volatile silicone fluids are commonly referred to as cyclomethicone.

[0174] (i) Cyclomethicone

[0175] Cyclomethicones are fully methylated cyclic siloxanes containing repeating units of formula (IV):

[0176] (IV)[-(CH 3 ) 2 SiO-] n

[0177] wherein n is 3, 4, 5, 6 or 7; or a mixture thereof. Cyclomethicone is a clear, colorless, volatile liquid silicone fluid. Cyclomethicone has emollient properties and helps improve the feel of oil-based products by reducing the greasy feel on the skin. Pharmaceutical grade cyclomethicone includes Cyclomethicone NF. Cyclomethicone NF is represented by formula (IV) wherein n is 4 (cyclotetrasiloxane), (cyclopentasiloxane) or 6 (cyclohexasiloxane); or a mixture thereof. Cyclopentasiloxane, also known as decamethylcyclopentasiloxane, cyclomethicone D5 or cyclomethicone 5, is a cyclomethicone represented by formula (IV) wherein n is 5 (pentamer), but it may contain small amounts (usually less than 1%) of one or more than one other cyclic chain length cyclomethicone. Cyclopentasiloxane is available in pharmaceutical grade as Cyclomethicone NF. Cyclomethicone is commercially available from Dow Corning under the trade names DOW CORNING ST-Cyclomethicone 5-NF, DOW CORNING ST-Cyclomethicone 56-NF, and XIAMETER PMX-0245. It is also commercially available from Spectrum Chemical Mfg. Corp. Cyclopentasiloxane has a vapor pressure of about 20 Pa to about 27 Pa at 25°C.

[0178] In one embodiment, the concentration of cyclomethicone in the composition is less than 25% by weight. In another embodiment, the concentration of cyclomethicone in the composition is from 5% to 24% by weight. In another embodiment, the concentration of cyclomethicone is from 5% to 20% by weight. In another embodiment, the concentration of cyclomethicone is from 5% to 18% by weight. In another embodiment, the concentration of cyclomethicone is 13% by weight. In various embodiments, the concentration of cyclomethicone can be 5%, 5.5%, 6%, 6.5%, 7%, 7.5%, 8%, 8.5%, 9%, 9.5%, 10%, 10.5%, 11%, 11.5%, 12%, 12.5%, 13%, 13.5%, 14%, 14.5%, 15%, 15.5%, 16%, 16.5%, 17%, 17.5%, 18%, 18.5%, 19%, 19.5%, 20%, 20.5%, 21%, 21.5%, 22%, 22.5%, 23%, 23.5%, or 24% by weight of the total weight of the composition, or any percentage obtainable therein. In one embodiment, the cyclomethicone is cyclopentasiloxane.

[0179] D. Aqueous Compositions

[0180] The aqueous composition of the present invention comprises taxane nanoparticles and an aqueous carrier. The aqueous preparation is a dispersion (suspension) of taxane nanoparticles in an aqueous carrier. The taxane nanoparticles can be completely dispersed, partially dispersed, and partially dissolved in the aqueous carrier, but cannot be completely dissolved in the aqueous carrier. The aqueous composition is a composition in which water is the main component. The aqueous carrier may include a single-phase aqueous solution and a multiphase aqueous emulsion, such as an oil-in-water emulsion and a water-in-oil emulsion.

[0181] Taxane nanoparticle crystals, such as paclitaxel nanoparticles, were observed to grow rapidly in water and aqueous vehicles. In many cases, growth was observed in only 3 days at room temperature, and in some cases within 24 hours. Many crystals were needle-shaped and greater than 5 μm in length. Studies were conducted and the results are shown in Table 2 of Example 2. Surprisingly, the crystal growth of taxane nanoparticles was inhibited by adding poloxamer 407, quaternary ammonium compounds, or cross-linked acrylic acid polymers to the aqueous vehicle during processing. Addition of poloxamer 188 did not inhibit the crystal growth of the nanoparticles.

[0182] It was also observed that the presence of a quaternary ammonium compound or a cross-linked acrylic polymer, or a mixture thereof, in an aqueous vehicle comprising taxane nanoparticle crystals prevented the growth of nanoparticle crystals over time. A study was conducted and the results are shown in Table 11 of Example 8, which revealed that the average particle size of poorly water-soluble taxane nanoparticles (paclitaxel) in an aqueous composition comprising poloxamer 407, a quaternary ammonium compound or a cross-linked acrylic polymer, or a mixture thereof, grew no more than 20% of the initial average particle size when the aqueous composition was stored at room temperature for 6 months. In some embodiments, an aqueous composition comprising an aqueous vehicle; a plurality of taxane nanoparticles; and a quaternary ammonium compound, or a cross-linked acrylic polymer, or a mixture thereof is disclosed; wherein the average particle size of the taxane nanoparticles is 0.1 microns to 1.5 microns (number average) or 0.01 microns to 1.5 microns (number average), and wherein the average particle size of the taxane nanoparticles grows no more than 20% of the initial average particle size when the composition is stored at room temperature for at least 6 months. In other embodiments, the composition further comprises poloxamer 407.

[0183] In one aspect of the invention, a composition comprising taxane nanoparticles, an aqueous carrier and poloxamer 407, a quaternary ammonium compound or a cross-linked acrylic polymer or a mixture thereof is disclosed. It was unexpectedly found that the addition of poloxamer 407, a quaternary ammonium compound or a cross-linked acrylic polymer inhibited the crystal growth of taxane nanoparticles in an aqueous carrier. The aqueous composition of the invention is suitable for topical injectable (IV) infusion or oral liquid dosage forms. In one embodiment, the additive that inhibits crystal growth is poloxamer 407. In various embodiments, the quaternary ammonium compound is the additive that inhibits crystal growth and is benzalkonium chloride or benzethonium chloride. In other embodiments, the quaternary ammonium compound is benzalkonium chloride. In other embodiments, the cross-linked acrylic polymer is the additive that inhibits crystal growth and is carbomer.

[0184] In one aspect of the invention, the composition comprising poloxamer 407 and taxane nanoparticles in an aqueous carrier is suitable for injectable delivery, including (IV) infusion. In various embodiments, the taxane nanoparticles are docetaxel nanoparticles, paclitaxel nanoparticles, or cabazitaxel nanoparticles.

[0185] In another aspect of the invention, the composition comprising a quaternary ammonium compound and taxane nanoparticles in an aqueous carrier is suitable for injection delivery, including (IV) infusion. In various embodiments, the taxane nanoparticles are docetaxel nanoparticles, paclitaxel nanoparticles, or cabazitaxel nanoparticles. In other embodiments, the quaternary ammonium compound is benzalkonium chloride or benzethonium chloride.

[0186] In one aspect of the present invention, a method of inhibiting the growth of a dispersion of crystalline taxane nanoparticles in an aqueous carrier is disclosed, the method comprising adding poloxamer 407, a quaternary ammonium compound, or a cross-linked acrylic polymer, or a mixture thereof, to the aqueous carrier during treatment, wherein the taxane nanoparticles have an average particle size of 0.1 microns to 1.5 microns (number average) or 0.01 microns to 1.5 microns (number average). In some embodiments, the quaternary ammonium compound is benzalkonium chloride or benzethonium chloride. In some embodiments, the cross-linked acrylic polymer is carbomer. In some embodiments, the taxane nanoparticles are paclitaxel nanoparticles, docetaxel nanoparticles, or cabazitaxel nanoparticles. In other embodiments, the taxane nanoparticles are paclitaxel nanoparticles.

[0187] (i) Poloxamer 407

[0188] Poloxamer 407 is a solid hydrophilic nonionic synthetic block copolymer of ethylene oxide and propylene oxide according to the general formula (V)

[0189] (V)HO(C 2 H 4 O) a (C 3 H 6 O) b (C 2 H 4 O) a H

[0190] Where a is 101 and b is 56. The average molecular weight of poloxamer 407 is 9840 to 14600. The term "poloxamer" is a non-exclusive name for copolymers. There are several types of poloxamers, which have various physical forms and various average molecular weights. Each specific poloxamer type is identified by the three digits following the non-exclusive name "poloxamer", the first two digits of which multiplied by 100 correspond to the approximate average molecular weight of the polyoxypropylene portion of the copolymer; the third digit multiplied by 10 corresponds to the weight percentage of the polyoxyethylene portion. Poloxamers are available in pharmaceutical, cosmetic and industrial grades. Pharmaceutical grade poloxamers have been listed in recognized pharmacopoeias, such as USP / NF and European Pharmacopoeia (PhEur). According to USP / NF and PhEur, suitable antioxidants may be added. Poloxamer 407 is available under the trade name F127 is commercially available from BASF. Addition of poloxamer 188 to an aqueous carrier does not inhibit the crystal growth of taxane nanoparticles. A suitable concentration of poloxamer 407 is at least 2 wt%, or 0.1 wt% to 25 wt%, or 0.1 wt% to 20 wt%, or 0.1 wt% to 15 wt%, or 0.1 wt% to 10 wt%, or 1 wt% to 25 wt%, or 1 wt% to 20 wt%, or 1 wt% to 15 wt%, or 1 wt% to 10 wt%, or 2 wt% to 25 wt%, or 2 wt% to 20 wt%, or 2 wt% to 15 wt%, or 2 wt% to 10 wt%.

[0191] (ii) Quaternary ammonium compounds

[0192] Quaternary ammonium compounds (including salts) are positively charged tetrasubstituted nitrogen derivatives of formula (VI)

[0193]

[0194] Where R 1 , R 2 , R 3 and R 4 may be the same or different, but may not be hydrogen. - Typical anions are described, for example chloride ions. Suitable quaternary ammonium compounds include benzalkonium chloride and benzethonium chloride. Benzalkonium chloride is commercially available as 100% powder or 50% aqueous solution. Other examples of quaternary ammonium compounds are disclosed in the International Cosmetic Ingredient Dictionary and Handbook, the 12th edition, 2008, which are incorporated herein by reference. The suitable concentration of quaternary ammonium compound is at least 0.05 % by weight, or at least 0.1 % by weight, or at least 1 % by weight, or at least 2 % by weight, or 0.05 % by weight to 5 % by weight, or 0.1 % by weight to 5 % by weight, or 1 % by weight to 5 % by weight, or 2 % by weight to 5 % by weight.

[0195] (iii) Cross-linked acrylic acid polymer

[0196] Crosslinked acrylic acid polymers are high molecular weight homopolymers and copolymers of acrylic acid crosslinked with polyalkenyl polyethers. Suitable crosslinked acrylic acid polymers include Carbomer (INCI name), Acrylates Copolymer (INCI name), Acrylates / C10-30 Alkyl Acrylate Crosspolymer (INCI name), Acrylates Crosspolymer-4 (INCI name), and Polyacrylate-1 Crosspolymer (INCI name). All of the above polymers are available under the trade name Commercially available from Lubrizol Corporation. Examples of carbomers available from Lubrizol Corporation include CARBOPOL 934, CARBOPOL 934P, CARBOPOL 940, CARBOPOL 980, CARBOPOL 941, CARBOPOL 981, CARBOPOL 2984, CARBOPOL 5984, CARBOPOL SILK 100, CARBOPOL ETD 2050, ULTREZ 10, and ULTREZ 30. Examples of acrylate copolymers available from Lubrizol Corporation include CARBOPOL AQUA SF-1 and CARBOPOL AQUA SF-1OS. Examples of acrylate / C10-30 alkyl acrylate crosspolymers available from Lubrizol include CARBOPOLULTREZ 20, CARBOPOL ULTREZ 21, CARBOPOL ETD 2020, CARBOPOL 1342, CARBOPOL 1382, and CARBOPOL SC-200. An example of an acrylate crosspolymer-4 is CARBOPOL AQUA SF-2. An example of a polyacrylate-1 crosspolymer is CARBOPOL AQUA CC. Suitable concentrations of the crosslinked acrylic polymer are at least 0.1 wt%, or 0.5 wt%, or 0.1 wt% to 5 wt%, or 0.5 wt% to 5 wt%.

[0197] E. Additional ingredients and adjuvants

[0198] The composition of the present invention can also include functional ingredients suitable for use in pharmaceutical compositions. Non-limiting examples include absorbents, acidulants, antibacterial agents, antioxidants, binders, antimicrobial agents, buffers, fillers, crystal growth inhibitors, chelating agents, colorants, deodorants, emulsion stabilizers, film formers, spices, wetting agents, solubilizers, enzyme preparations, opacifiers, oxidants, pH regulators, plasticizers, preservatives, reducing agents, emollients, skin moisturizing conditioners, moisturizers, surfactants, emulsifiers, cleansers, foaming agents, water-soluble promoters (hydrotopes), solvents, suspending agents, viscosity control agents (rheology modifiers), viscosity increasing agents (thickeners) and propellants. The list and monograph of the examples of the functional ingredients described herein are disclosed in the International Cosmetic Ingredient Dictionary and Handbook (INCI), the 12th edition, 2008, which is incorporated herein by reference.

[0199] The compositions of the invention may also contain additional pharmaceutical active ingredients, cosmetic active ingredients and veterinary drugs suitable for topical use.

[0200] Although the hydrophobic composition of the present invention may also include an additional penetration enhancer, it was found that it is not necessary to include an additional penetration enhancer in order to increase the skin penetration (i.e., into the epidermis and dermis of the skin) of the taxane nanoparticles in a hydrophobic composition comprising a hydrophobic carrier and one or more volatile silicone fluids. In fact, the addition of a skin penetration enhancer has little or no effect on the skin penetration of the hydrophobic composition.

[0201] The term "penetration enhancer" has been used to describe compounds or materials or substances that promote drug absorption through the skin. These compounds or materials or substances can directly affect the permeability of the skin, or can increase percutaneous absorption by increasing the thermodynamic activity of the penetrant, thereby increasing the effective escape trend and concentration gradient of the diffused substance. The main effect of these enhancers is to increase the hydration of the stratum corneum or destroy its lipoprotein matrix, and the final result in both cases is to reduce the resistance (Remington, The Science and Practice of Pharmacy, the 22nd edition) to the diffusion of drugs (penetrants).

[0202] Non-limiting examples of skin penetration enhancers include oleyl alcohol, isopropyl myristate, isosorbide dimethyl ether (DMI) obtained under the trade name ARLASOLVE DMI, and diethylene glycol monoethyl ether (DGME) obtained under the trade name TRANSCUTOL P. Other examples of skin penetration enhancers can be found in "Skin Penetration Enhancers Cited in the Technical Literature", Osborne, David W. and Henke, Jill J., Pharmaceutical Technology, November 1997, which is incorporated herein by reference. These examples include: fatty alcohols, such as aliphatic alcohols, alcohol), decyl alcohol, lauryl alcohol (dodecanol), linoleyl alcohol, nerolidol, 1-nonanol, n-octanol, oleyl alcohol, fatty acid esters, butyl acetate, cetyl lactate, N,N-dimethylaminoacetic acid decyl ester, N,N-dimethylaminoisopropionic acid decyl ester, diethylene glycol oleate, diethyl sebacate, diethyl succinate, diisopropyl sebacate, N,N-dimethylaminoacetic acid dodecyl ester, (N,N-dimethylamino)-butyric acid dodecyl ester, N,N-dimethylaminoisopropionic acid dodecyl ester, 2- (Dimethylamino) dodecyl propionate, EO-5-oleate, ethyl acetate, ethyl acetoacetate, ethyl propionate, glyceryl monoether, glyceryl monolaurate, glyceryl monooleate, glyceryl monolinoleate, isopropyl isostearate, isopropyl linoleate, isopropyl myristate, isopropyl myristate / fatty acid monoglyceride combination, isopropyl myristate / ethanol / L-lactic acid (87:10:3) combination, isopropyl palmitate, methyl acetate, methyl caprate, methyl laurate, methyl propionate, methyl valerate, 1 -Monocaproylglycerol, monoglycerides (medium chain length), nicotinate (benzyl ester), octyl acetate, N,N-dimethylamino octyl acetate, oleyl oleate, N-acetyl proline n-pentyl ester, propylene glycol monolaurate, sorbitan dilaurate, sorbitan dioleate, sorbitan monolaurate, sorbitan monooleate, sorbitan trilaurate, sorbitan trioleate, sucrose coconut fatty acid ester mixture, sucrose monolaurate, sucrose monooleate and N, N-dimethylaminoacetic acid myristyl; fatty acids, such as alkanoic acid, capric acid, dioctadecanoic acid, ethyloctadecanoic acid, caproic acid, lactic acid, lauric acid, trans-linoleic acid, linoleic acid, linolenic acid, neodecanoic acid, oleic acid, palmitic acid, nonanoic acid, propionic acid and vaccenic acid; fatty alcohol ethers, such as α-monoglyceryl ether, EO-2-oleyl ether, EO-5-oleyl ether, EO-10-oleyl ether and polyglycerols and ether derivatives of alcohols (1-O-dodecyl-3-O-methyl-2-O-(2',3'-dihydroxypropyl)glycerol);Biological agents, such as L-α-amino acids, lecithin, phospholipids, saponins / phospholipids, sodium deoxycholate, sodium taurocholate, and sodium cholate; enzymes, such as acid phosphatase, Calonase, hyaluronidase, papain, phospholipase A-2, phospholipase C, and triacylglycerol hydrolase; amines and amides, such as acetamide derivatives, acyclic amides, N-adamantyl n-alkaneamide, clofibric acid amide, N,N-docosylacetamide, di-2-ethylhexylamine, diethylmethylbenzamide, N,N-diethyl-m-toluamide, N,N-dimethyl-m-toluamide, Ethomeen S12 [bis-(2-hydroxyethyl) oleylamine], hexamethylene lauramide, laurylamine (dodecylamine), caprylamide, oleamide, unsaturated cyclic ureas and ureas; complexing agents such as β-cyclodextrin and γ-cyclodextrin complexes, hydroxypropyl methylcellulose, liposomes, naphthalene diamide diimide and naphthalene diester diimide; macrocyclic compounds such as macrolides, ketones and anhydrides (optimally 16 rings) and unsaturated cyclic ureas; typical surfactants such as Brij 30, Brij 35, Brij 36T, Brij 52, Brij 56, Brij 58, Brij 72, Brij 76, Brij 78, Brij 92, Brij 96, Brij 98, hexadecyltrimethylammonium bromide, Empicol ML26 / F, HCO-60 surfactant, hydroxypolyethoxydodecane, ionic surfactants (ROONa, ROSO; 3 Na、RNH 3 Cl, R = 8 to 16), lauroyl sarcosine, nonionic surfactant, nonoxynol ether, octoxynol, benzene sulfonate CA, Pluronic F68, Pluronic F 127, Pluronic L62, polyoleate (nonionic surfactant), Rewopal HV 10, sodium laurate, sodium lauryl sulfate (sodium dodecyl sulfate), sodium oleate, sorbitan dilaurate, sorbitan dioleate, sorbitan monolaurate, sorbitan monooleate, sorbitan trilaurate, sorbitan trioleate, Span 20, Span 40, Span85, Synperonic NP, Triton X-100, Tween 20, Tween 40, Tween 60, Tween 80 and Tween 85; N-methylpyrrolidone and related compounds such as N-cyclohexyl-2-pyrrolidone, 1-butyl-3-dodecyl-2-pyrrolidone, 1,3-dimethyl-2-imidazolone, 1,5-dimethyl-2-pyrrolidone, 4,4-dimethyl-2-undecyl-2- oxazoline, 1-ethyl-2-pyrrolidone, 1-hexyl-4-methoxycarbonyl-2-pyrrolidone, 1-hexyl-2-pyrrolidone, 1-(2-hydroxyethyl)pyrrolidone, 3-hydroxy-N-methyl-2-pyrrolidone, 1-isopropyl-2-undecyl-2-imidazoline, 1-lauryl-4-methoxycarbonyl-2-pyrrolidone, N-methyl-2-pyrrolidone, poly(N-vinylpyrrolidone), pyroglutamate and 2-pyrrolidone (2-pyrrolidone); ionic compounds such as ascorbate, zwitterionic cations and anions, calcium thioglycolate, cetyltrimethylammonium bromide, sodium 3,5-diiodosalicylate, lauroylcholine iodide, sodium 5-methoxysalicylate, monoalkyl phosphates, 2-PAM chloride, 4-PAM chloride (derivative of N-methylpyridinium chloride), sodium carboxylates and sodium hyaluronate; dimethyl sulfoxide and related compounds, such as cyclosulfoxide, decyl methyl sulfoxide, dimethyl sulfoxide (DMSO), and 2-hydroxyundecyl methyl sulfoxide; solvents and related compounds, such as acetone, n-alkanes (chain length 7 to 16), cyclohexyl-1,1-dimethylethanol, dimethylacetamide, dimethylformamide, ethanol, ethanol / d-limonene combination, 2-ethyl-1,3-hexanediol, ethoxydiglycol (TRANSCUTOL), glycerol, ethylene glycol, lauroyl chloride, limonene, N-methylformamide, 2-phenylethanol, 3-phenyl-1-propanol, 3-phenyl-2-propan-1-ol, polyethylene glycol, polyoxyethylene sorbitan monoester, polypropylene glycol, primary alcohol (tridecanol), propylene glycol, squalene, triacetin, trichloroethanol, trifluoroethanol, trimethylene glycol, and xylene;Azones and related compounds, such as N-acyl-hexahydro-2-oxo-1H-azepane, N-alkyl-dihydro-1,4-oxazepane-5,7-dione, N-alkylmorpholine-2,3-dione, N-alkylmorpholine-3,5-dione, azacycloalkane derivatives (-ketones, -thiones), azacycloalkenone derivatives, 1-[2-(decylthio)ethyl]azacyclopentane-2-one (HPE-101), N-(2,2-dihydroxyethyl)dodecylamine, 1-dodecanoylhexahydro-1-H-azepane triene (azepine), 1-dodecylazacycloheptane-2-one (azepine or lauryl azone), N-dodecyldiethanolamine, N-dodecylhexahydro-2-thio-1H-azepine, N-dodecyl-N-(2-methoxyethyl)acetamide, N-dodecyl-N-(2-methoxyethyl)isobutyramide, N-dodecyl-piperidine-2-thione, N-dodecyl-2-piperidone, N-dodecylpyrrolidine-3,5-dione, N-dodecylpyrrolidine-2-thione, N-dodecyl -2-pyrrolidone, 1-farnesylazacycloheptane-2-one, 1-farnesylazacyclopentane-2-one, 1-geranylazacycloheptane-2-one, 1-geranylazacyclopentane-2-one, hexahydro-2-oxo-azacycloheptane-1-acetate, N-(2-hydroxyethyl)-2-pyrrolidone, 1-laurylazacycloheptane, 2-(1-nonyl)-1,3-dioxolane, 1-N-octylazacyclopentane-2-one, N-(1-oxydodecyl)-hexahydro-1H-azacycloheptane, N-(1-oxydodecyl)- )-morpholine, 1-oxoalkyl-substituted azacyclohexane, N-(1-oxotetradecyl)-hexahydro-2-oxo-1H-azacycloheptatriene and N-(1-thiododecyl)-morpholine; and others such as aliphatic thiols, N,N-dialkyl-substituted aminoacetic acid alkyl esters, anise oil, anticholinergic pretreatment, astridol, biphasic group derivatives, bisabolol, cardamom oil, 1-carvone, quinoa (70% astridol), quinoa oil, 1,8-cineole (eucalyptol), cod liver oil (fatty acid extract), 4-decyl; Oxazolidin-2-one, dicyclohexylmethylamine oxide, diethyl hexadecylphosphonate, diethyl hexadecyl pyrophosphoramide, N,N-dimethyldodecylamine-N-oxide, 4,4-dimethyl-2-undecyl-2- Oxazoline, N-dodecanoyl-L-amino acid methyl ester, 1,3-dioxane (SEPA), dithiothreitol, eucalyptol (cineole), eucalyptus oil, eugenol, herbal extracts, lactam N-acetate, N-hydroxyethalaceamide, N-hydroxyethylacetamide, 2-hydroxy-3-oleyloxy-1-pyroglutamyloxypropane, menthol, menthone, morpholine derivatives, N-oxides, nerolidol, octyl-β-D-(thio)pyranoglucoside, Oxazolidinone, piperazine derivatives, polar lipids, polydimethylsiloxane, poly[2-(methylsulfinyl)ethyl acrylate], polyrotaxane, polyvinylbenzyldimethylalkylammonium chloride, poly(N-vinyl-N-methylacetamide), sodium pyroglutamate, terpenes and nitrogen heterocyclic compounds, vitamin E (α-tocopherol), vitamin E TPGS and ylang ylang oil. Other examples of penetration enhancers not listed above can be found in the "Handbook of Pharmaceutical Excipients", fifth edition, including tetraethylene glycol, lanolin, light mineral oil, myristic acid, polyoxyethylene alkyl ethers and thymol. Other examples of penetration enhancers include ethanolamine, diethanolamine, triethanolamine, diethylene glycol, monoethyl ether, citric acid, succinic acid, borage oil, tetrahydropiperine (THP), methanol, ethanol, propanol, octanol, benzyl alcohol, myristyl alcohol, cetyl alcohol, stearyl alcohol and polyethylene glycol monolaurate.

[0203] Although the hydrophobic composition of the present invention may also contain alcohol, the composition does not necessarily contain alcohol, C 1 To C 4 Fatty alcohol or C 1 To C 5 In some aspects of the invention, the composition does not contain C 1 To C 4 Fatty alcohol or C 1 To C 5 Fatty alcohol.

[0204] Although the hydrophobic composition of the present invention may also include additional volatile solvents, it is not necessary for the hydrophobic composition to include additional volatile solvents. Volatile solvents are also referred to as "escape" solvents. Non-limiting examples of volatile solvents include volatile alcohols, such as C 1 To C 4 Fatty alcohol; and volatile C 1 To C 4 In some aspects of the invention, the composition is free of / does not contain volatile C 1 To C 4 In some aspects of the invention, the composition is free of / does not contain volatile C 1 To C 4 Fatty alcohol.

[0205] Although the hydrophobic composition of the present invention may also include a surfactant, the hydrophobic composition does not necessarily include a surfactant. The term "surfactant" refers to a compound or material or substance that exhibits the ability to reduce the surface tension of water or reduce the interfacial tension between two immiscible substances, including anionic surfactants, cationic surfactants, nonionic surfactants, amphoteric surfactants and / or phospholipid surfactants. Non-limiting examples of surfactants can be found in McCutcheon's Emulsifiers and Detergents, 2001, North American Edition, which is incorporated herein by reference, and the International Cosmetic Ingredient Dictionary and Handbook (INCI), 12th Edition, 2008, which is incorporated herein by reference. Examples include, but are not limited to: block polymers such as poloxamer 124; ethoxylated alcohols such as ceteth-2, ceteareth-20, laureth-3; ethoxylated fatty acid esters and oils such as PEG-40 hydrogenated castor oil, PEG-36 castor oil, PEG-150 distearate; glyceryl esters such as polyglyceryl-3 diisostearate, glyceryl stearate; glycol esters, PEG-12 dioleate, LEXEMUL P; phosphate esters, such as cetyl phosphate; polymer surfactants, such as PVM / MA copolymers, acrylates / C10 to 30 alkyl acrylate cross-linked copolymers; quaternary ammonium surfactants, such as hexadecyl trimethyl ammonium chloride; silicone-based surfactants, such as PEG / PPG-20 / 6 dimethicone; sorbitan derivatives, such as sorbitan stearate, polysorbate 80; sucrose and glucose esters and derivatives, such as PEG-20 methyl glucose sesquistearate; and alcohol sulfates, such as sodium lauryl sulfate. More generally, surfactants can be classified by their ion type, such as anionic surfactants, cationic surfactants, nonionic surfactants or amphoteric surfactants. They can also be classified by their chemical structure, such as block polymers, ethoxylated alcohols, ethoxylated fatty acid esters and oils, glycerides, glycol esters, phosphate esters, polymer surfactants, quaternary ammonium surfactants, silicone-based surfactants, sorbitan derivatives, sucrose and glucose esters and derivatives, and alcohol sulfates.

[0206] F. Manufacturing

[0207] The composition of the present invention can be manufactured by methods and equipment known in the art for manufacturing pharmaceutical products including locally injectable products and oral liquid products. Such methods include, but are not limited to, the use of mechanical mixers, dissolvers, dispersers, homogenizers and grinders. Non-limiting examples include LIGHTNIN propeller mixers, COWLES dissolvers, IKA ULTRA TURRAX dispersers, SILVERSON homogenizers, LEE counter-rotating side scraping mixers, production lines and rotor-stator homogenizers in tanks, 3-roller grinders, ointment grinders and rotor-stator grinders. An "all-in-one" vacuum mixing system with a rotating side scraping mixer and a tank homogenizer can also be used. Such mixers include, but are not limited to, OLSA mixers, FRYMA-KORUMA mixers and LEE TRI-MIX TURBO-SHEAR kettles. The composition of the present invention can be manufactured from small-scale laboratory batches using laboratory mixing equipment to large-scale batches.

[0208] II. Enhanced Local Delivery Methods

[0209] In one aspect of the present invention, a method of enhancing the penetration of taxane nanoparticles into skin malignancies (including skin cancers and / or skin metastases) is disclosed, the method comprising applying a topical composition disclosed herein to the affected area of ​​the skin malignancy. In a preferred embodiment, the method comprises applying a hydrophobic composition to the affected area of ​​the skin malignancy, the hydrophobic composition comprising a hydrophobic carrier, one or more than one volatile silicone fluid, and a plurality of taxane nanoparticles. In some embodiments, the taxane nanoparticles are paclitaxel nanoparticles, docetaxel nanoparticles, or cabazitaxel nanoparticles. In some embodiments, the taxane nanoparticles, including paclitaxel nanoparticles, docetaxel nanoparticles, or cabazitaxel nanoparticles, have a size of 0.01 micron to 1.5 micron, or 0.01 micron to 1.2 micron, or 0.01 micron to 1 micron, or 0.01 micron to less than 1 micron, or 0.01 micron to 0.9 micron, or 0.01 micron to 0.8 micron, or 0.01 micron to 0.7 micron, or 0.1 micron to 1.5 micron, or 0.1 micron to 1.2 micron, or 0.01 micron to 1.5 micron, or 0.01 micron to 1.2 micron, or 0.01 micron to 0.9 micron, or 0.01 micron to 0.8 micron, or 0.01 micron to 0.7 micron, or 0.1 micron to 1.5 micron, or 0. ... .1 micron to 1 micron, or 0.1 micron to less than 1 micron, or 0.1 micron to 0.9 micron, or 0.1 micron to 0.8 micron, or 0.1 to 0.7 micron, or 0.2 micron to 1.5 micron, or 0.2 micron to 1.2 micron, or 0.2 micron to 1 micron, or 0.2 micron to less than 1 micron, or 0.2 micron to 0.9 micron, or 0.2 micron to 0.8 micron, or 0.2 micron to 0.7 micron, or 0.3 micron to 1.5 micron, or 0.3 micron to 1.2 micrometer, or 0.3 micrometer to 1 micrometer, or 0.3 micrometer to less than 1 micrometer, or 0.3 micrometer to 0.9 micrometer, or 0.3 micrometer to 0.8 micrometer, or 0.3 micrometer to 0.7 micrometer, or 0.4 micrometer to 1.5 micrometer, or 0.4 micrometer to 1.2 micrometer, or 0.4 micrometer to 1 micrometer, or 0.4 micrometer to less than 1 micrometer, or 0.4 micrometer to 0.9 micrometer, or 0.4 micrometer to 0.8 micrometer, or 0.4 micrometer to 0.7 micrometer, or 0.5 micrometer to 1.5 micrometer, or 0. The taxane nanoparticles have an average particle size (number average) of at least 1.5 μm to 1.2 μm, or 0.5 μm to 1 μm, or 0.5 μm to less than 1 μm, or 0.5 μm to 0.9 μm, or 0.5 μm to 0.8 μm, or 0.5 μm to 0.7 μm, or 0.6 μm to 1.5 μm, or 0.6 μm to 1.2 μm, or 0.6 μm to 1 μm, or 0.6 μm to less than 1 μm, or 0.6 μm to 0.9 μm, or 0.6 μm to 0.8 μm, or 0.6 μm to 0.7 μm. In other embodiments, the taxane nanoparticles are paclitaxel nanoparticles. In some embodiments, the SSA of the paclitaxel nanoparticles is at least 18 μm. 2 / g, at least 19m 2 / g, at least 20m 2 / g, at least 21m 2 / g, at least 22m 2 / g, at least 23m 2 / g, at least 24m 2 / g, at least 25m 2 / g, at least 26m 2 / g, at least 27m 2 / g, at least 28m 2 / g, at least 29m 2 / g, at least 30m 2 / g, at least 31m 2 / g, at least 32m 2 / g, at least 33m 2 / g, at least 34m 2 / g or at least 35m 2 In other embodiments, the SSA of the paclitaxel nanoparticles is 18 m 2 / g to 50m 2 / g, 20m 2 / g to 50m 2 / g, 22m 2 / g to 50m 2 / g, 25m 2 / g to 50m 2 / g, 30m 2 / g to 50m 2 / g, 18m 2 / g to 45m 2 / g, 20m 2 / g to 45m 2 / g, 22m 2 / g to 45m 2 / g, 25m 2 / g to 45m 2 / g, 30m 2 / g to 45m 2 / g, 18m 2 / g to 40m 2 / g, 20m 2 / g to 40m 2 / g, 22m 2 / g to 40m 2 / g, 25m 2 / g to 40m 2 / g, 30m 2 / g to 40m 2 In some embodiments, the bulk density (non-tapped density) of the paclitaxel nanoparticles is 0.05 g / cm 3 Up to 0.15g / cm 3 or 0.05g / cm 3Up to 0.20g / cm 3 . In various embodiments, the hydrophobic carrier is non-polar and / or non-volatile. In some embodiments, the hydrophobic carrier comprises a hydrocarbon. In other embodiments, the hydrophobic carrier comprises a mineral ester, a mineral oil and / or a paraffin. In some embodiments, the mineral oil is a heavy mineral oil. In some embodiments, the concentration of the volatile silicone fluid in the composition formulation is an amount that effectively enhances the skin penetration of the taxane nanoparticles compared to a formulation without a volatile silicone fluid. A suitable method for measuring penetration into a skin malignancy can be by using an in vitro Franz diffusion cell (FDC) system of human cadaver skin. A suitable in vitro Franz diffusion cell system is described in Example 9 below. In some embodiments, the concentration of one or more volatile silicone fluids is 5% to 24% by weight. In other embodiments, the concentration of one or more volatile silicone fluids is 5% to 20% by weight. In other embodiments, the concentration of one or more volatile silicone fluids is 5% to 18% by weight. In other embodiments, the concentration of the one or more volatile silicone fluids is 13 wt %. In various embodiments, the concentration of the one or more volatile silicone fluids can be 5 wt %, 5.5 wt %, 6 wt %, 6.5 wt %, 7 wt %, 7.5 wt %, 8 wt %, 8.5 wt %, 9 wt %, 9.5 wt %, 10 wt %, 10.5 wt %, 11 wt %, 11.5 wt %, 12 wt %, 12.5 wt %, 13 wt %, 13.5 wt %, 14 wt %, 15 wt %, 16 wt %, 17 wt %, 18 wt %, 19 wt %, 20 wt %, 21 wt %, 22 wt %, 23 wt %, 24 wt %, 25 wt %, 26 wt %, 27 wt %, 28 wt %, 29 wt %, 30 wt %, 31 wt %, 32 wt %, 33 wt %, 34 wt %, 35 wt %, 36 wt %, 37 wt %, 38 wt %, 39 wt %, 40 wt %, 41 wt %, 42 wt %, 43 wt %, 44 wt %, 45 wt %, 46 wt %, 47 wt %, 48 wt %, 49 wt %, 14.5 wt%, 15 wt%, 15.5 wt%, 16 wt%, 16.5 wt%, 17 wt%, 17.5 wt%, 18 wt%, 18.5 wt%, 19 wt%, 19.5 wt%, 20 wt%, 20.5 wt%, 21 wt%, 21.5 wt%, 22 wt%, 22.5 wt%, 23 wt%, 23.5 wt%, or 24 wt%, or any percentage obtainable therein. In various embodiments, one or more than one volatile silicone fluid is cyclomethicone. In other embodiments, the cyclomethicone is cyclopentasiloxane. In some embodiments, the hydrophobic composition does not include additional penetration enhancers. In other embodiments, the hydrophobic composition does not include additional volatile solvents. In other embodiments, the hydrophobic composition does not include surfactants. In other embodiments, the hydrophobic composition does not have / does not include alcohol, C 1 To C 4 Fatty alcohol or C 1 To C 5Fatty alcohol. In various embodiments, the taxane can be paclitaxel, docetaxel or cabazitaxel. In some embodiments, the skin malignancy is skin cancer or skin metastasis. In some embodiments, the hydrophobic composition is anhydrous. In other embodiments, the hydrophobic composition is sterile. In other embodiments, the hydrophobic composition is non-sterile. In other embodiments, the hydrophobic composition has a low bioburden. In some embodiments, the hydrophobic composition is a semisolid composition. In other embodiments, the hydrophobic composition is an ointment. In some embodiments, the hydrophobic composition is a semisolid composition, including an ointment, and has a viscosity of 12500cps to 247500cp, or 25000cp to 150000cp measured at room temperature using a Brookfield RV viscometer with a small sample adapter with an SC4-14 rotor and a 6R chamber at 5rpm and a 2-minute equilibrium time. An alternative method for measuring the viscosity of a hydrophobic semisolid composition is to use a Brookfield RV viscometer on a lift stand with a TE spindle connected at 10 RPM, room temperature for 45 seconds. In some embodiments, the hydrophobic composition is a semisolid composition, including an ointment, and has a viscosity of 25,000 cp to 500,000 cp, or 25,000 cp to 400,000 cp, or 25,000 cp to 350,000 cp, or 25,000 cp to 300,000 cp, or 50,000 cp to 500,000 cp, or 50,000 cp to 400,000 cp, or 50,000 cp to 350,000 cp, or 50,000 cp to 400,000 cp, or 50,000 cp to 350,000 cp, or 50,000 cp to 350,000 cp, or 50,000 cp to 50 ...350,000 cp, or 50,000 cp to In some embodiments, the hydrophobic composition is not a spray and is not sprayable.

[0210] In another aspect of the present invention, a method of enhancing the penetration of taxane nanoparticles into a skin malignancy is disclosed, the method comprising topically applying a hydrophobic composition comprising a plurality of taxane nanoparticles to the surface of the skin malignancy, wherein the penetration of the taxane nanoparticles in the hydrophobic composition is greater than the penetration of the taxane nanoparticles in a suspension of the taxane nanoparticles in an aqueous composition. A suitable method for determining the penetration of taxane nanoparticles into a skin malignancy is an in vitro Franz diffusion cell (FDC) system using human cadaver skin. A suitable in vitro Franz diffusion cell system is described in Example 9 below. In some embodiments, the taxane nanoparticles have an average particle size (number average) of 0.1 microns to 1.5 microns. In other embodiments, the taxane nanoparticles are paclitaxel nanoparticles, docetaxel nanoparticles, or cabazitaxel nanoparticles. In other embodiments, the hydrophobic composition further comprises a hydrophobic carrier. In other embodiments, the skin malignancy is a skin cancer or a skin metastasis.

[0211] III. Methods for Inhibiting Crystal Growth in Formulations

[0212] In one aspect of the present invention, a method of inhibiting the growth of crystallized taxane nanoparticles is disclosed, the method comprising contacting the taxane nanoparticles with a hydrophobic carrier. In some embodiments, the taxane nanoparticles are paclitaxel nanoparticles, docetaxel nanoparticles, or cabazitaxel nanoparticles. In some embodiments, the taxane nanoparticles are paclitaxel nanoparticles. In other embodiments, the composition is anhydrous. In other embodiments, the hydrophobic carrier comprises a hydrocarbon. In other embodiments, the hydrocarbon is petrolatum, mineral oil, or paraffin or a mixture thereof. In some embodiments, the mineral oil is a heavy mineral oil. In some embodiments, the composition further comprises one or more than one volatile silicone fluid. In other embodiments, the volatile silicone fluid is cyclomethicone. In other embodiments, the cyclomethicone is cyclopentasiloxane.

[0213] In another aspect of the present invention, a method of inhibiting the growth of a dispersion of crystalline taxane nanoparticles in an aqueous carrier is disclosed, the method comprising adding poloxamer 407, a quaternary ammonium compound, or a cross-linked acrylic polymer to the aqueous carrier during manufacture. In some embodiments, the additive is poloxamer 407. In various embodiments, the quaternary ammonium compound is an additive and is benzalkonium chloride or benzethonium chloride. In some embodiments, the quaternary ammonium compound is benzalkonium chloride. In some embodiments, the cross-linked acrylic polymer is an additive and is a carbomer. In some embodiments, the taxane nanoparticles are paclitaxel nanoparticles, docetaxel nanoparticles, or cabazitaxel nanoparticles.

[0214] IV. Topical treatment of skin malignancies

[0215] The methods of the present invention include methods of treating a patient's skin malignancy (including skin cancer and skin metastases) by topically applying a composition disclosed herein comprising a taxane to the affected area (topical therapy). An "affected area" of a skin malignancy may include at least a portion of the skin where a skin malignancy lesion (tumor) is evident on the outermost surface of the skin or just below the surface of the skin (epithelial / dermal covering), and may include areas of the skin near the skin malignancy that may contain apparently undetectable preclinical lesions. In some embodiments, the taxane is paclitaxel. In other embodiments, the taxane is docetaxel or cabazitaxel. In some aspects, the composition is hydrophobic and may include a hydrophobic carrier. In other aspects, the composition is an aqueous composition and may include an aqueous carrier. In some embodiments, the carrier is anhydrous. In some embodiments, the taxane is a plurality of taxane nanoparticles. In some embodiments, a plurality of taxane nanoparticles are suspended in the composition. In other aspects, the taxane is dissolved in the composition.

[0216] A preferred method for topical treatment of skin malignancies comprises topically applying to the affected area a hydrophobic composition comprising a continuous hydrophobic carrier, one or more than one volatile silicone fluid, and a plurality of taxane nanoparticles, wherein the taxane nanoparticles are suspended in the composition, wherein the taxane nanoparticles have an average particle size (number average) of 0.1 microns to 1.5 microns or 0.01 microns to 1.5 microns, and wherein the concentration of the taxane nanoparticles is an amount effective to provide a therapeutic improvement in the skin malignancy condition. In some embodiments, the taxane nanoparticles are paclitaxel nanoparticles, docetaxel nanoparticles, or cabazitaxel nanoparticles. In some embodiments, the taxane nanoparticles, including paclitaxel nanoparticles, docetaxel nanoparticles, or cabazitaxel nanoparticles, have a size of 0.01 micron to 1.5 micron, or 0.01 micron to 1.2 micron, or 0.01 micron to 1 micron, or 0.01 micron to less than 1 micron, or 0.01 micron to 0.9 micron, or 0.01 micron to 0.8 micron, or 0.01 micron to 0.7 micron, or 0.1 micron to 1.5 micron, or 0.1 micron to 1.2 micron, or 0.01 micron to 1.5 micron, or 0.01 micron to 1.2 micron, or 0.01 micron to 0.9 micron, or 0.01 micron to 0.8 micron, or 0.01 micron to 0.7 micron, or 0.1 micron to 1.5 micron, or 0. ... .1 micron to 1 micron, or 0.1 micron to less than 1 micron, or 0.1 micron to 0.9 micron, or 0.1 micron to 0.8 micron, or 0.1 to 0.7 micron, or 0.2 micron to 1.5 micron, or 0.2 micron to 1.2 micron, or 0.2 micron to 1 micron, or 0.2 micron to less than 1 micron, or 0.2 micron to 0.9 micron, or 0.2 micron to 0.8 micron, or 0.2 micron to 0.7 micron, or 0.3 micron to 1.5 micron, or 0.3 micron to 1.2 micrometer, or 0.3 micrometer to 1 micrometer, or 0.3 micrometer to less than 1 micrometer, or 0.3 micrometer to 0.9 micrometer, or 0.3 micrometer to 0.8 micrometer, or 0.3 micrometer to 0.7 micrometer, or 0.4 micrometer to 1.5 micrometer, or 0.4 micrometer to 1.2 micrometer, or 0.4 micrometer to 1 micrometer, or 0.4 micrometer to less than 1 micrometer, or 0.4 micrometer to 0.9 micrometer, or 0.4 micrometer to 0.8 micrometer, or 0.4 micrometer to 0.7 micrometer, or 0.5 micrometer to 1.5 micrometer, or 0. 5 μm to 1.2 μm, or 0.5 μm to 1 μm, or 0.5 μm to less than 1 μm, or 0.5 μm to 0.9 μm, or 0.5 μm to 0.8 μm, or 0.5 μm to 0.7 μm, or 0.6 μm to 1.5 μm, or 0.6 μm to 1.2 μm, or 0.6 μm to 1 μm, or 0.6 μm to less than 1 μm, or 0.6 μm to 0.9 μm, or 0.6 μm to 0.8 μm, or 0.6 μm to 0.7 μm. In other embodiments, the taxane nanoparticles are paclitaxel nanoparticles. In some embodiments, the paclitaxel nanoparticles have an average particle size (number average) of at least 18 μm. 2 / g, at least 19m 2 / g, at least 20m 2 / g, at least 21m 2 / g, at least 22m 2 / g, at least 23m 2 / g, at least 24m 2 / g, at least 25m 2 / g, at least 26m 2 / g, at least 27m 2 / g, at least 28m 2 / g, at least 29m 2 / g, at least 30m 2 / g, at least 31m 2 / g, at least 32m 2 / g, at least 33m 2 / g, at least 34m 2 / g or at least 35m 2 In other embodiments, the paclitaxel nanoparticles have an SSA of 18 m 2 / g to 50m 2 / g, or 20m 2 / g to 50m 2 / g, or 22m 2 / g to 50m 2 / g, or 25m 2 / g to 50m 2 / g, or 30m 2 / g to 50m 2 / g, or 18m 2 / g to 45m 2 / g, or 20m 2 / g to 45m 2 / g, or 22m 2 / g to 45m 2 / g, or 25m 2 / g to 45m 2 / g, or 30m 2 / g to 45m 2 / g, or 18m 2 / g to 40m 2 / g, or 20m 2 / g to 40m 2 / g, or 22m 2 / g to 40m 2 / g, or 25m 2 / g to 40m 2 / g, or 30m 2 / g to 40m 2 In some embodiments, the bulk density (non-tapped density) of the paclitaxel nanoparticles is 0.05 g / cm 3 Up to 0.15g / cm 3or 0.05g / cm 3 Up to 0.20g / cm 3 . In various embodiments, the hydrophobic carrier is non-polar and / or non-volatile. In some embodiments, the hydrophobic carrier comprises hydrocarbons. In other embodiments, the hydrophobic carrier comprises mineral esters, mineral oil and / or paraffin. In some embodiments, the mineral oil is a heavy mineral oil. In some embodiments, the concentration of the volatile silicone fluid is 5% to 24% by weight. In other embodiments, the concentration of the volatile silicone fluid is 5% to 20% by weight. In other embodiments, the concentration of the volatile silicone fluid is 5% to 18% by weight. In other embodiments, the concentration of the volatile silicone fluid is 13% by weight. In some embodiments, the volatile silicone fluid is cyclomethicone. In other embodiments, cyclomethicone is cyclopentasiloxane. In various embodiments, the hydrophobic composition does not / does not include additional penetration enhancers. In some embodiments, the hydrophobic composition does not / does not include laurocapram and / or diethylene glycol monoethyl ether (DGME) and / or isopropyl myristate and / or alpha-tocopherol. In other embodiments, the hydrophobic composition does not contain / does not contain additional volatile solvents. In other embodiments, the hydrophobic composition does not contain / does not contain surfactants. In other embodiments, the hydrophobic composition does not contain / does not contain alcohols, C 1 To C 4 Fatty alcohol or C 1 To C 5 Fatty alcohol. In some embodiments, the hydrophobic composition comprises one or more than one volatile silicone fluid, but does not comprise additional silicone materials. In some embodiments, the hydrophobic composition is free of / does not comprise hyaluronic acid; and / or is free of / does not comprise a combination of hyaluronic acid and taxane; and / or is free of / does not comprise a combination of hyaluronic acid and paclitaxel; and / or is free of / does not comprise a polymer or a biodegradable polymer; and / or is free of / does not comprise a poloxamer, styrene-isobutylene-styrene (SIBS), a polyanhydride copolymer, polycaprolactone, polyethylene glycol, poly(bis(p-carboxyphenoxy)propane-sebacic acid and / or poly(D,L-lactic-co-glycolic acid (PLGA).

[0217] The concentration of the taxane nanoparticles is effective to provide a therapeutic improvement in the symptoms of the skin malignancy. Such improvement can be demonstrated by visual observation and post-treatment measurement of the affected area to include at least one of the following effects: (a) reduction in the size of the skin malignancy lesion (tumor); (b) reduction in the number of skin malignancy lesions (tumors); (c) elimination of the skin malignancy lesions (tumors); (d) reduction in pain at the site of the skin malignancy lesion (tumor). The concentration of the taxane nanoparticles may be 0.05 wt % to 10 wt % of the total weight of the composition, or the concentration of the taxane nanoparticles may be 0.05 wt % to 5 wt % of the total weight of the composition, or the concentration of the taxane nanoparticles may be 0.1 wt % to 5 wt % of the total weight of the composition, or the concentration of the taxane nanoparticles may be 0.05 wt %, 0.1 wt %, 0.15 wt %, 0.2 wt %, 0.25 wt %, 0.3 wt %, 0.4 wt %, 0.5 wt %, 0.6 wt %, 0.7 wt %, 0.75 wt %, 0.8 wt %, 0.9 wt %, 1.0 wt %, 1.1 wt %, 1.2 wt %, 1.25 wt %, 1.3 wt %, 1.4 wt %, 1.5 wt %, 1.6 wt %, 1.7 wt %, 1.75 wt %, 1.8 wt %, 1.9 wt % of the total weight of the composition %, 2.0 wt%, 2.1 wt%, 2.2 wt%, 2.25 wt%, 2.3 wt%, 2.4 wt%, 2.5 wt%, 2.6 wt%, 2.7 wt%, 2.75 wt%, 2.8 wt%, 2.9 wt%, 3.0 wt%, 3.1 wt%, 3.2 wt%, 3.25 wt%, 3.3 wt%, 3.4 wt%, 3.5 wt%, 3.6 wt%, 3.7 wt%, %, 3.75 wt%, 3.8 wt%, 3.9 wt%, 4.0 wt%, 4.1 wt%, 4.2 wt%, 4.25 wt%, 4.3 wt%, 4.4 wt%, 4.5 wt%, 4.6 wt%, 4.7 wt%, 4.75 wt%, 4.8 wt%, 4.9 wt%, 5 wt%, 6 wt%, 7 wt%, 8 wt%, 9 wt%, or 10 wt%, or any obtainable percentage therein. In some embodiments, the taxane nanoparticles are paclitaxel nanoparticles, docetaxel nanoparticles, or cabazitaxel nanoparticles. In other embodiments, the taxane nanoparticles are paclitaxel nanoparticles.In some embodiments, the concentration of paclitaxel nanoparticles in the composition is about 0.05 wt % to less than 3 wt %, or about 0.05 wt % to about 2 wt %, or about 0.05 wt % to about 1 wt %, or about 0.05 wt % to about 0.3 wt %, or about 0.05 wt % to about 0.2 wt %, or about 0.05 wt % to about 0.15 wt %, or about 0.1 wt % to about 2 wt %, or about 0.1 wt % to about 1 wt %, or about 0.1 wt % to about 0.3 wt %, or about 0.1 wt % to about 0.2 wt %, or about 0.15 wt % to about 2 wt %, or about 0.15 wt % to about 1 wt %, or about 0.15 wt % to about 0.3 wt %, or about 0.3 wt % to about 2 wt %, or about 0.3 wt % to about 1 wt %, or about 1 wt % to about 2 wt %, or about 0.2 wt % to about 0.4 wt %, or about 0.5 wt % to about 1.5 wt %, or about 1.5 wt % to about 2.5 wt %. In other embodiments, the concentration of paclitaxel nanoparticles is 1 wt% of 80% to 120% (i.e., 0.8 wt% to 1.2 wt%), or 0.05 wt% of 80% to 120%, or 0.1 wt% of 80% to 120%, or 0.15 wt% of 80% to 120%, or 0.2 wt% of 80% to 120%, or 0.25 wt% of 80% to 120%, or 0.3 wt% of 80% to 120%, or 0.35 wt% of 80% to 120%, or 0.4 wt% of 80% to 120%, or 0.45 wt% of 80% to 120%, or 0.5 wt% of 80% to 120%. % to 120%, or 0.55% by weight of 80% to 120%, or 0.6% by weight of 80% to 120%, or 0.65% by weight of 80% to 120%, or 0.7% by weight of 80% to 120%, or 0.75% by weight of 80% to 120%, or 0.8% by weight of 80% to 120%, or 0.85% by weight of 80% to 120%, or 0.9% by weight of 80% to 120%, or 0.95% by weight of 80% to 120%, or 1.5% by weight of 80% to 120%, or 2% by weight of 80% to 120%, or 2.5% by weight of 80% to 120%.

[0218] In some embodiments, the hydrophobic composition is sterile. In other embodiments, the hydrophobic composition is unsterilized. In other embodiments, the hydrophobic composition has a low bioburden. In other embodiments, the hydrophobic composition is anhydrous. In some embodiments, the hydrophobic composition is a semisolid composition. In other embodiments, the hydrophobic composition is an ointment. In some embodiments, the hydrophobic composition is a semisolid composition, including an ointment, and has a viscosity of 12500cp to 247500cp or 25000cp to 150000cp, which is measured at room temperature using a Brookfield RV viscometer with a small sample adapter with an SC4-14 rotor and a 6R chamber with a 5rpm and 2-minute equilibrium time. An alternative method for measuring the viscosity of a hydrophobic semisolid composition is to use a Brookfield RV viscometer to connect a TE rotor on a lifting stand to measure 45 seconds at 10RPM, room temperature. In some embodiments, the hydrophobic composition is a semisolid composition, including an ointment, and has a viscosity of 25,000 cp to 500,000 cp, or 25,000 cp to 400,000 cp, 25,000 cp to 350,000 cp, or 25,000 cp to 300,000 cp, or 50,000 cp to 500,000 cp, or 50,000 cp to 400,000 cp, or 50,000 cp to 350,000 cp, or 50,000 cp to 30,000 cp. In some embodiments, the hydrophobic composition has a viscosity of 10000 cp to 500000 cp, or 75000 cp to 400000 cp, or 75000 cp to 350000 cp, or 75000 cp to 300000 cp, or 100000 cp to 500000 cp, or 100000 cp to 400000 cp, or 100000 cp to 350000 cp, or 100000 cp to 300000 cp, the viscosity being measured using a Brookfield RV viscometer on a lift stand connected to a TE rotor at 10 RPM, room temperature for 45 seconds. In some embodiments, the hydrophobic composition is not a spray and is not sprayable. In some embodiments, the composition is not a dry powder. In some embodiments, the composition comprises more than just taxane nanoparticles.

[0219] In some embodiments, the skin malignancy is skin cancer. The methods of the present invention can be used to treat various skin cancers, including but not limited to melanoma, basal cell carcinoma, squamous cell carcinoma and Kaposi's sarcoma (including Kaposi's sarcoma associated with AIDS). In other embodiments, the skin malignancy is a skin metastasis. The methods of the present invention can be used to treat skin metastases derived from various primary cancers. Skin metastases can be from but not limited to one or more of the following primary malignancies: breast malignancy, lung malignancy, nasal malignancy, sinus malignancy, laryngeal malignancy, oral malignancy, colon (large intestine) malignancy, rectal malignancy, stomach malignancy, ovarian malignancy, testicular malignancy, bladder malignancy, prostate malignancy, cervical malignancy, vaginal malignancy, thyroid malignancy, endometrial malignancy, kidney malignancy, esophageal malignancy, pancreatic malignancy, liver malignancy, melanoma and Kaposi's sarcoma. In some embodiments, skin metastases are from lung cancer, breast cancer, colon cancer, oral cancer, ovarian cancer, kidney cancer, esophageal cancer, stomach cancer or liver cancer. In some embodiments, the skin metastasis is from breast cancer.In some embodiments, the skin metastasis is a non-melanoma skin metastasis.

[0220] The amount of the hydrophobic composition applied topically to the affected area of ​​the skin malignancy can vary depending on the size of the affected area and the concentration of paclitaxel in the composition, but can generally be applied in a manner that is about the thickness of a dime to completely cover the affected area. Another suitable method for determining the amount of the composition applied is the "fingertip unit" (FTU) method. One FTU is the amount of the topical composition squeezed from a standard tube along the fingertip of an adult (assuming that the tube has a standard nozzle of 5 mm). The fingertip is from the very end of the finger to the first crease of the finger. The composition can be applied with a gloved hand or a spatula or other topical administration method. In some embodiments, the composition is applied to a skin malignancy with complete skin coverage (epithelial / skin coverage). In some embodiments, the composition is applied to an ulcerated area, where the skin malignancy lesion is on the surface of the skin or where the skin coverage is broken down and the skin malignancy lesion is exposed. In some embodiments, the composition is not applied to an ulcerated area. The affected area can be gently cleaned with water (if necessary, with a neutral soap) and dried before application. Once the composition is applied, an occlusive dressing such as or Cover the application site. The dosage of the composition can vary, but can generally include once a day, twice a day, or three times a day at about the same time each day until the condition is improved or eliminated. Through the treatment methods disclosed herein, the treatment improvement of the skin malignancy condition can be shown by visual observation and measurement of the affected area after treatment, including at least one of the following effects: (a) reducing the size of the skin malignancy lesion (tumor); (b) reducing the number of skin malignancy lesions (tumors); (c) eliminating the skin malignancy lesions (tumors); (d) reducing the pain at the site of the skin malignancy lesion (tumor).

[0221] Example

[0222] The present invention will be described in more detail by way of specific examples. The following examples are provided only for illustrative purposes and are not intended to limit the present invention in any way. Those skilled in the art will readily recognize various noncritical parameters that can be changed or modified to produce substantially the same results.

[0223] Example 1 - Solubility of Paclitaxel in Various Solvents

[0224] The solubility of paclitaxel in various solvents was determined by the following method: (a) for each solvent, approximately 2 g of solvent was weighed into a clear glass vial, (b) approximately 0.1 g of paclitaxel was added to each vial, (c) each vial was stirred at room temperature for 2 hours on a magnetic stirrer with a stir bar, (d) each vial was then checked every 1 to 2 hours to see if the solution had become clear. If so, approximately 0.1 g of paclitaxel was added to the vial and mixing continued. Step "d" was continued for each vial for a total of 48 hours.

[0225] The paclitaxel concentration of the solution in each vial was measured using an HPLC method based on the Agilent Technical Application Note for Paclitaxel, “Analysis of Paclitaxel by HPLC” (2002), modified to use a detection wavelength of 227 nm instead of 204 nm (the 227 nm wavelength is used in the USP paclitaxel monograph and reduces solvent effects observed at lower wavelengths).

[0226] The solubility values ​​are shown in Table 1.

[0227] Table 1

[0228]

[0229]

[0230] Example 2 Observation of Paclitaxel Nanoparticle Crystals in Various Substances and Substance Solutions

[0231] Paclitaxel nanoparticles were dispersed in various substances and aqueous solutions of the substances, and their crystal growth was observed. The results are shown in Table 2.

[0232] Table 2

[0233]

[0234]

[0235] Paclitaxel nanoparticle crystals did not grow in any of the hydrophobic carriers. In addition, nanoparticles did not grow in aqueous solutions of benzalkonium chloride, CARBOPOL ULTREZ 10, or Poloxamer 407.

[0236] Example 3 Particle size, SSA and bulk density analysis of paclitaxel nanoparticles

[0237] The particle size of the paclitaxel nanoparticle batches used in the formulations listed in Table 3 and Tables 16 to 19 was analyzed using ACCUSIZER 780 by the following particle size method:

[0238] Instrument parameters : Maximum concentration: 9000 particles / mL, Number of containers: 1, Sensor range: Total, Lower detection limit: 0.5μm, Flow rate: 30mL / min, Number of pull analyses: 4, Pull interval: 1 second, Pull volume: 10mL, Tare volume: 1mL, Prime volume: 1mL, Include first pull: Not selected.

[0239] Sample preparation : Place one scoop of paclitaxel nanoparticle API into a clean 20 mL vial and add approximately 3 mL of filtered (0.22 μm) 0.1 wt% SDS solution to wet the API, then fill the rest of the vial with SDS solution. Vortex for 5 to 10 minutes and sonicate in a water bath for 1 minute.

[0240] method : Fill a plastic bottle with a 0.1 wt% SDS solution after filtering (0.22 μm) and analyze the background. While stirring, pipette a small amount (<100 μL) of the paclitaxel nanoparticle sample suspension into the 0.1 wt% SDS solution bottle; place the ACCUSIZER inlet tube into the bottle and run the sample analysis through the instrument. Add more SDS solution or paclitaxel sample suspension as needed to achieve the desired running concentration of 6000 to 8000 particle counts.

[0241] Particle size results(Differential distribution based on number weight): The batches of paclitaxel nanoparticles used in the formulation are listed in Table 3: Mean: 0.861 μm, Mode: 0.572 μm, Median: 0.710 μm. The batches of paclitaxel nanoparticles used in the formulation are listed in Tables 16 to 19: Mean: 0.83 μm.

[0242] The specific surface area (SSA) of the batch of paclitaxel nanoparticles used in the formulations listed in Table 3 and Tables 16 to 19 was analyzed by the above-mentioned specific adsorption surface ("BET") isotherm method. The SSA of the batch of paclitaxel nanoparticles used in the formulation listed in Table 3 was 41.24 m 2 / g. The SSA of the paclitaxel nanoparticle batches used in the formulations listed in Tables 16 to 19 was 26.72 m 2 / g.

[0243] The bulk density (not tapped density) of the paclitaxel nanoparticle batch used in the formulation listed in Table 3 was 0.05 g / cm 3 The bulk density (non-tapped density) of the paclitaxel nanoparticle batches used in the formulations listed in Tables 16 to 19 was 0.09 g / cm 3 .

[0244] Example 4 Anhydrous hydrophobic compositions of paclitaxel nanoparticles with a hydrophobic carrier Table 3 lists anhydrous hydrophobic compositions of paclitaxel nanoparticles with a hydrophobic carrier.

[0245] Table 3

[0246]

[0247] Procedure for F4 to F13: Prepare a slurry of paclitaxel nanoparticles with a portion of cyclopentasiloxane (or mineral oil (F4) or FOMBLIN (F7)). Heat the mineral oil to 52±3°C, add the remaining ingredients and mix until melted and homogeneous. Add the paclitaxel slurry and mix until homogeneous. Mix and cool the batch to 35°C or below. Form an ointment.

[0248] Example 5 Physical and Chemical Stability of Anhydrous Compositions of Paclitaxel Nanoparticles with Hydrophobic Carriers

[0249] The anhydrous hydrophobic composition samples were stored in 20 mL glass scintillation counting vials at 25°C and 30°C. The determination of paclitaxel was performed using HPLC. The test results and the appearance stability study are shown in Tables 4 and 5 below. The viscosity was measured at room temperature using a Brookfield RV viscometer using a small sample adapter with an SC4-14 rotor and a 6R chamber at 5 rpm and a 2-minute equilibrium time. The viscosity results are shown in Table 6 below.

[0250] Table 4 - Stability at 25°C

[0251]

[0252] **Repeat batches

[0253] Table 5 - Stability at 30°C

[0254]

[0255] **Repeat batches

[0256] Table 6 - Viscosity stability

[0257]

[0258] Example 6 Particle Size Analysis of Paclitaxel Nanoparticles in Anhydrous Compositions with Hydrophobic Carriers The particle size method was used using ACCUSIZER Model 770 / 770A.

[0259] Instrument parameters : Sensor: LE 0.5μm to 400μm, Sensor Range: Total, Lower Detection Limit: 0.5μm, Collection Time: 60 sec, Number of Channels: 128, Vessel Fluid Volume: 100mL, Flow Rate: 60 / mL / min, Maximum Coincidence: 8000 particles / mL, Sample Container: Accusizer Container, Sample Calculation: No, Voltage Detector: Greater than 10V, Particle Concentration Calculation: No, Concentration Range: 5000 particles / mL to 8000 particles / mL, Autosave Data: Selected, Subtract Background: Yes, Number of Auto Cycles: 1.

[0260] Sample preparation : Add an aliquot of the sample preparation to a scintillation counting vial. Use a spatula to spread the sample along the inside of the vial. Add approximately 20 mL of 2% lecithin in ISOPAR-G to the vial. TM (C10 to C11 Isoparaffin) solution. Sonicate the vial for 1 minute. Ensure that the sample is well dispersed in the solution.

[0261] method: Fill the sample container with a filtered (0.22 μm) 2% lecithin ISOPAR-G solution and analyze the background. Use a pipette to transfer a portion of the prepared sample to the container while stirring. Dilute or add samples to the container as needed to provide a consistent level of 5000 to 8000 particles / mL. Start analysis with the instrument and demonstrate a consistent level of 5000 to 8000 particles / mL for analysis.

[0262] The results of the particle size analysis are shown in Tables 7 and 8 below.

[0263] Table 7 - Particle size stability at 25°C

[0264]

[0265] **Repeat batches

[0266] Table 8 - Particle size stability at 30°C

[0267]

[0268] **Repeat batches

[0269] It can be seen from the data that when stored at room temperature (25°C) and 30°C for 1 month, the particle size growth of the paclitaxel nanoparticles in samples F4 to F6 is no more than 20% of the initial average particle size. When stored at room temperature (25°C) and 30°C for 6 months and 12 months, the particle size growth of the paclitaxel nanoparticles in sample F6 is no more than 20% of the initial average particle size. When stored at room temperature (25°C) and 30°C for 3 months, the particle size growth of the paclitaxel nanoparticles in samples F6** (a repeated batch with the same formulation as F6) and F8 to F13 is no more than 20% of the initial average particle size.

[0270] Example 7 Aqueous Composition of Paclitaxel Nanoparticles

[0271] Table 9 shows the aqueous compositions of paclitaxel nanoparticles.

[0272] Table 9

[0273]

[0274] The crystal growth of paclitaxel nanoparticles in the samples was observed. The results are shown in Table 10 below.

[0275] Table 10

[0276]

[0277] From the data it can be seen that the presence of benzalkonium chloride, CARBOPOL 974P or CARBOPOL ULTREZ 10 inhibits the growth of crystals in the aqueous compositions.

[0278] Example 8 Particle Size Analysis of Paclitaxel Nanoparticles in Aqueous Compositions

[0279] Particle size method using ACCUSIZER Model 770 / 770A.

[0280] Instrument parameters: Sensor: LE 0.5μm to 400μm, Sensor Range: Total, Lower Detection Limit: 0.5μm, Collection Time: 60 sec, Number of Channels: 128, Vessel Fluid Volume: 100mL, Flow Rate: 60 / mL / min, Maximum Consistency: 8000 particles / mL, Sample Container: Accusizer Container, Sample Calculation: No, Voltage Detector: Greater than 10V, Particle Concentration Calculation: No, Concentration Range: 5000 particles / mL to 8000 particles / mL, Autosave Data: Selected, Subtract Background: Yes, Number of Auto Cycles: 1.

[0281] Sample preparation : Add an aliquot of the sample preparation to a scintillation counting vial. Use a spatula to spread the sample along the inside wall of the vial. Add approximately 20 mL of 0.2 μm filtered distilled water to the vial. Sonicate the vial for 1 minute. Ensure that the sample is well dispersed in the solution.

[0282] method : Fill the sample container with 0.2 μm filtered distilled water and analyze the background. Use a pipette to transfer a portion of the prepared sample to the container while stirring. Dilute or add samples to the container as needed to provide a consistent level of 5000 to 8000 particles / mL. Start analysis with the instrument, demonstrating a consistent level of 5000 to 8000 particles / mL for analysis.

[0283] The results of the particle size analysis are shown in Table 11 below.

[0284] Table 11 Particle size of aqueous composition

[0285]

[0286] From the data of formulations F1, F2 and F3 in Table 11, it can be seen that the presence of benzalkonium chloride, CARBOPOL 974P or CARBOPOL ULTREZ 10 inhibits the growth of crystals in the aqueous composition, so that when the composition is stored at room temperature for 6 months, the average particle size of the drug nanoparticles does not grow by more than 20% of the initial average particle size.

[0287] Example 9 In vitro skin permeation and diffusion study

[0288] A study was conducted to determine the rate and extent of in vitro skin penetration of formulations F1 to F13 into and through intact human cadaver skin using a Franz diffusion cell system. The concentration of paclitaxel was measured in the receptor compartment of the diffusion cell at various time points. After the diffusion study was completed, the skin was stripped with tape and separated into the epidermis and dermis. Paclitaxel in the epidermis and dermis tissues was extracted using an extraction solvent and analyzed.

[0289] Analytical Methods: A mass spectrometry (MS) method was developed for the analysis of paclitaxel. The MS conditions are shown in Table 12 below.

[0290] Table 12

[0291]

[0292] Franz Diffusion Cell (FDC) Research - Methodology

[0293] Skin preparation: Intact human cadaveric skin was purchased from the New York Firefighters Tissue Bank (NFFTB). Skin was collected from the upper back and approximately 500 μm of skin was taken through the tissue bank. After receiving the skin from the tissue bank, the skin was stored frozen at -20°C until the morning of the experimental day. Before use, the skin was removed from the refrigerator and allowed to thaw completely at room temperature. The skin was then briefly soaked in a PBS bath to remove any residual cryoprotectant and preservative. During the experiment, only visually intact skin areas were used. For each study, two separate donors were used, each with corresponding three replicate samples.

[0294] Receptor fluid preparation: Based on preliminary solubility data results, a receptor fluid of 96 wt% phosphate buffered saline ("PBS") at pH 7.4 and 4 wt% hydroxypropyl beta-cyclodextrin (HPBCD) was selected. The solubility of the active substance in the receptor fluid (approximately 0.4 μg / mL) has been shown to be sufficient to maintain sedimentation conditions during the study. The receptor fluid was degassed by filtering the receptor fluid through a ZapCapCR 0.2 μm membrane while applying vacuum. The filtered receptor fluid was stirred for an additional 20 minutes while maintaining vacuum to ensure complete degassing.

[0295] Diffusion Cell Assembly: Remove the cadaver skin from the refrigerator and defrost in the biosafety hood for 30 minutes. Thoroughly defrost the skin before opening the package. Remove the cadaver skin from the package and place it on the biosafety hood countertop with the stratum corneum facing up. Dry the skin with a Kim Wipe, then spray it with fresh PBS and wipe it dry again. Repeat this process 3 more times to remove any residue present on the skin. The receptor wells are then filled with degassed receptor fluid. A Teflon-coated stirring bar is added to each receptor well. Inspect the defrosted cadaver skin and only use areas with uniform thickness and no visible damage on the surface. Cut the skin into squares of approximately 2 cm x 2 cm. The skin piece is located in the center of the donor well with the stratum corneum (SC) facing up. Center the skin and flatten the edges. The donor well and receptor well are then aligned and clamped together with a clamp. Add additional receptor fluid if necessary. Remove any bubbles present by tilting the cell to allow air to escape along the sample port. The diffusion cell is then placed in a stirred dry heater and allowed to rehydrate from the receptor fluid for 20 minutes. The dry block heater was maintained at 32°C with continuous stirring throughout the experiment. The skin was allowed to hydrate for 20 minutes and the barrier integrity of each skin section was tested. Upon completion of the membrane integrity examination study, the entire receptor chamber volume was replaced with receptor fluid.

[0296] Formulation application process: The formulation was applied to the stratum corneum of the skin. This study used a one-time dosing regimen. The test article was applied to the skin at a dose of 10 μl using a positive displacement Nichiryo pipette. The formulation was then spread on the skin surface using a glass rod. The cells were left uncapped during the experiment. The theoretical dose of paclitaxel per cell is shown in Table 13 below.

[0297] Table 13

[0298]

[0299] * Repeat analysis

[0300] Receptor fluid sampling: At 3 hours, 6 hours, 12 hours, and 24 hours, remove 300 μL sample aliquots from the receptor wells using a graduated Hamilton-type syringe. Add fresh receptor medium to replace the 300 μL sample aliquots.

[0301] Tape stripping and thermal splitting: At 24 hours, the skin was wiped clean using Kim Wipes soaked in PBS / ethanol. After wiping off the residual preparation and drying the skin with Kim Wipes, the stratum corneum was tape stripped 3 times, and each tape stripping consisted of applying a cellophane tape to the skin under uniform pressure and peeling it off. The tape strips were collected and frozen for future analysis. The first three tape strips removed the uppermost layer of the stratum corneum and served as an additional skin cleaning step. It is generally believed that the active substance is not completely absorbed in this area. Mass balance analysis is usually performed only on these tape strips. After the skin is stripped with tape, each piece of epidermis is then separated from the underlying dermis tissue using forceps or a spatula. The epidermal and dermal tissues are collected and placed in 4 mL borosilicate glass vials. After all the skin is separated, an aliquot of the extraction solvent is added to the glass vial. The process consists of adding 2 mL DMSO to the vial and incubating at 32°C for 24 hours. After the extraction time was complete, a sample aliquot of 300 μL of the extract was collected and filtered.

[0302] Sample Analysis: Sample aliquots were analyzed for paclitaxel using the analytical method described above.

[0303] result:

[0304] The results in Table 14 below show the delivered dose of paclitaxel (μg / cm 2 ) (transdermal flux) and the concentration of paclitaxel delivered in the epidermis and dermis (μg / cm 2 )(penetration). Figure 1 The concentration of paclitaxel delivered to the epidermis for formulations F1 to F7 is shown graphically (μg / cm 2 ). Figure 2 The concentration of paclitaxel delivered to the epidermis (μg / cm2) for formulations F6* (analyzed in duplicate) and F8 to F13 is shown graphically. 2 ). Figure 3 The concentration of paclitaxel delivered into the dermis (μg / cm 2 ). Figure 4 The concentration of paclitaxel delivered to the dermis (μg / cm2) for formulations F6* (analyzed in duplicate) and F8 to F13 is shown graphically. 2 ).

[0305] Note: Formulations F1 to F6 were tested in one in vitro study, and formulations F6* and F8 to F13 were tested in a separate in vitro study with a different batch of cadaver skin. The analysis of formulation F6 (denoted F6*) was repeated in another study so that it could be evaluated and compared with the other formulations in the second study.

[0306] Table 14

[0307]

[0308]

[0309] * Repeat analysis

[0310] It can be seen from the results in Table 14 that the transdermal flux of paclitaxel through the skin (epidermis and dermis) is zero or only a negligible amount, i.e., less than 0.01 μg / cm 2 From Table 14 and Figure 1 , Figure 2 , Figure 3 and Figure 4 As can be seen from the results, the penetration of paclitaxel into the skin (epidermis and dermis) of the anhydrous hydrophobic formulations (F4 to F13) is much greater than that of the aqueous formulations (F1 to F3), even though the aqueous formulations contain the skin penetration enhancer DGME (TRANSCUTOL P). The results also show that the anhydrous hydrophobic formulations with cyclomethicone exhibit greater skin penetration (epidermis and dermis) than the anhydrous hydrophobic formulations without cyclomethicone. In addition, the results show that the addition of other skin penetration enhancers to the anhydrous hydrophobic formulations containing cyclomethicone has little or no effect on the skin penetration (epidermis and dermis) of these compositions.

[0311] Example 10 - Formulations for Skin Metastasis Studies

[0312] The following ointment formulations shown in Table 15 were prepared for use in skin metastasis studies.

[0313] Table 15

[0314]

[0315] The formulations containing paclitaxel nanoparticles listed in Table 15 were all manufactured in batches of 6 kg. The formulations were then packaged in 15 g laminate tubes.

[0316] The manufacturing process of batches F14, F15 and F16 is as follows: petrolatum, mineral oil, paraffin wax and part of cyclomethicone are added to a container and heated to 52 ± 3 ° C while mixing with a propeller mixer until melted and uniform. Paclitaxel nanoparticles are added to a container containing another part of cyclomethicone, then mixed with a spatula to wet the nanoparticles, and then mixed with an IKA Ultra Turrax homogenizer with an S25-25G dispersion tool until a uniform slurry is obtained while the container is kept in an ice / water bath. The slurry is then added to the petrolatum / paraffin wax container while mixing with a propeller mixer, and then rinsed and mixed with the remaining part of the cyclomethicone until the batch is visually uniform while being at 52 ± 3 ° C. The batch is then homogenized using a Silverson homogenizer. Afterwards, the batch is mixed with a propeller mixer until a uniform ointment is formed, and the batch is cooled to 35 ° C or below.

[0317] The manufacturing process of batch F17 is as follows: add petrolatum and paraffin to a container and heat to 52 ± 3 ° C while mixing with a propeller mixer until melted and uniform. Paclitaxel nanoparticles are added to a container containing cyclomethicone and a portion of mineral oil, then mixed with a spatula to wet the nanoparticles, and then mixed with an IKA Ultra Turrax homogenizer with an S25-25G dispersion tool until a uniform slurry is obtained while the container is kept in an ice / water bath. The slurry is then added to the petrolatum / solid paraffin container while mixing with a propeller mixer, then rinsed and mixed with the remaining portion of mineral oil until the batch is visually uniform and at 52 ± 3 ° C. The batch is then homogenized using a Silverson homogenizer. Afterwards, the batch is mixed with a propeller mixer until a uniform ointment is formed, and the batch is cooled to 35 ° C or below.

[0318] The results of chemical and physical analyses of each formulation in Table 15 at T=0, 1 month and 3 months at 25°C are shown in Tables 16 to 19.

[0319] Table 16

[0320]

[0321] Note 1: Off-white to yellow ointment

[0322] Note 2: Measured with a Brookfield RV viscometer on a lift stand with a TE spindle at 10 RPM at room temperature for 45 seconds.

[0323] Table 17

[0324]

[0325] Note 1: Off-white to yellow ointment

[0326] Note 2: Measured with a Brookfield RV viscometer on a lift stand with a TE spindle at 10 RPM at room temperature for 45 seconds.

[0327] Table 18

[0328]

[0329] Note 1: Off-white to yellow ointment

[0330] Note 2: Measured with a Brookfield RV viscometer on a lift stand with a TE spindle at 10 RPM at room temperature for 45 seconds.

[0331] Table 19

[0332]

[0333] Note 1: Off-white to yellow ointment

[0334] Note 2: Measured with a Brookfield RV viscometer on a lift stand with a TE spindle at 10 RPM at room temperature for 45 seconds.

[0335] Example 11 - Individual Patient Expanded Access Trial for Local Treatment of Cutaneous Metastatic Breast Cancer

[0336] The formulations in Table 15 are used in an individual human patient extension pathway trial for topical treatment of cutaneous metastatic breast cancer. In this extension pathway trial, subjects with skin metastases from breast cancer will receive a 0.3% paclitaxel nanoparticle ointment (formulation F15 in Table 15) applied topically to the affected area. Prior to the start of the study, historical information will be collected from the subject, including history of surgery, radiation, chemotherapy, and time to ulceration of other skin metastases. Before the start of treatment, photographs (with rulers) will be taken at the clinic and the metastases (treated areas) will be measured. No biopsies or blood tests will be performed. Before application, the treated area will be gently cleaned with water (if necessary, with neutral soap) and dried. The ointment will be applied to the metastases where the subject has skin coverage (epithelial / dermal coverage) with a gloved hand. The ointment is not applied to ulcerated areas. A layer of "dime thickness" of ointment will be applied to the metastases as directed by the clinical staff at the first treatment. The application site of the ointment is covered with an occlusive dressing (TEGADERM or SOLOSITE). The subject will be treated once again for two weeks at approximately the same time every day using the same technique as the initial administration for metastases. The subject will then return to the clinic to check the response, and any adverse events will be recorded in the clinical record. Photos of the treatment site (with a ruler) will be taken and the lesions will be measured. Subjects can be treated for another two weeks with the approval of the doctor, and the subject will return to the clinic for a final visit, where photos of the treatment site (with a ruler) will be taken and the lesions will be measured. Adverse events will be recorded in the clinical record. If the subject and the doctor request, after checking the data and discussing with the doctor, a higher or lower dose can be authorized according to the above plan. No washout period is required. If the subject and the doctor request, after checking the data and discussing with the doctor, further treatment with the same dose (0.3% paclitaxel nanoparticle ointment), increasing dose (1.0% and / or 2.0% paclitaxel nanoparticle ointment) or decreasing dose (0.15% paclitaxel nanoparticle ointment) can be authorized. If erythema, rupture or ulceration occurs, the subject will wash the treatment area with water (and mild soap if necessary) and return to the clinic for evaluation. Photos (with ruler) will be taken of the treatment area, the lesions will be measured, and no further ointment will be applied unless approved by the physician. The endpoint of the trial will show a reduction in skin metastases demonstrating treatment improvement of the skin metastatic condition.

[0337] Example 12 - Phase 1 / 2 Dose Escalation, Safety, Tolerability, and Efficacy Study in Skin Metastases

[0338] The three formulations in Table 15 above are used in a 1 / 2 phase dose increase, safety, tolerability and efficacy study of human skin metastases approved by the FDA. The study is currently ongoing. This is a 1 / 2 phase open-label dose increase study that evaluates the safety, tolerability and preliminary efficacy of the three formulations in Table 15: F14 (0.15%), F16 (1.0%) and F17 (2.0%) are topically applied twice daily to non-melanoma skin metastases for 28 days.

[0339] Based on the RECIST (version 1.1) definition of measurable tumors (greater than or equal to 10 mm in longest diameter), a 50-cm area on the trunk or limb containing at least one qualifying lesion was identified. 2 All lesions within the treatment area were measured with a caliper to confirm eligibility. One fingertip unit (FTU) of the formulation was applied to the subject 50 cm away at approximately the same time twice daily using a gloved hand. 2 The treatment area was maintained for 28 days. FTU was defined as the amount of ointment formulation squeezed out of a tube with a 5 mm diameter mouth, applied from the distal skin crease of the index finger of an adult to the tip of the index finger. Subjects visited the clinic on Day 1 to receive dosing training and observe the first treatment application. Additional visits were made on Days 8, 15, 29, and 43. A final visit was completed 30 days after the last dose of study drug to check for adverse events. Study participation was divided into a dose escalation phase and a dose expansion phase.

[0340] Dose escalation phase: In the dose escalation phase, the study followed a standard 3+3 dose escalation design: the first three subjects began treatment with F14 formulation (0.15%). After the last subject in each batch of three subjects completed treatment for 15 days, the safety monitoring committee reviewed all available data to determine whether dose escalation could continue.

[0341] Dose Expansion Phase: In the dose expansion phase, additional subjects are enrolled at the dose levels determined in the dose escalation phase to reach a total of up to 12 subjects. Subjects in the dose expansion phase are seen on the same visit days and receive the same assessments as in the dose escalation phase described above.

[0342] Objectives: The primary objective of the study is to determine the preliminary safety and tolerability of the formulation. Secondary objectives are to determine the preliminary efficacy of the formulation, to investigate the potential relief of pain in the treated area, and to describe the pharmacokinetics of the formulation administered to metastatic lesions.

[0343] Population: Minimum of two to maximum of 24 male and female subjects, aged greater than or equal to 18 years, with non-melanoma skin metastases.

[0344] Primary objective: Safety and tolerability, as demonstrated by adverse events, changes in laboratory assessments, physical examination findings, and vital signs.

[0345] Secondary objectives: For the following secondary objectives for efficacy, eligible lesions were determined based on the RECIST (version 1.1) definition of measurable tumors whose longest diameter was greater than or equal to 10 mm (EISENHAUER et al., New response evaluation criteria in solid tumors: revised RECIST guidelines (version 1.1). European Journal of Cancer. 2009; 45; 228-247).

[0346] Objective tumor response is defined as the difference of the sum of qualified tumor diameters in the treatment area between baseline and the 43rd day (i.e. 14 days after the last administration in the dose escalation and expansion phase of the dosage regimen). Tumor surface area and response were assessed at all visits. The change of surface area was assessed using the calibration grid measurement system (ImageJ free software) provided by the National Institutes of Health (NIH). ImageJ was used to measure and analyze lesions.

[0347] Objective clinical response was defined as subjects with a complete clinical response (CR) + partial response (PR), which was further defined as the percentage of patients who achieved a complete clinical response or partial response 14 days after the last treatment with the agent, measured as the change in the sum of the longest diameters of eligible target lesions within the treatment area 14 days after the last treatment. Response to treatment was evaluated as the total diameter after treatment divided by the total diameter before treatment.

[0348] Best overall response was defined as the best response recorded from the start of study treatment to the end of treatment (i.e., day 43).

[0349] A complete clinical response (CR) was defined as the absence of any detectable residual disease in eligible lesions in the treated area; a partial response (PR) was a decrease of at least 30% in the sum of diameters of eligible lesions in the treated area compared to baseline; progressive disease (PD) was an increase of at least 20% in the sum of diameters of eligible lesions in the treated area, using the smallest sum in the study as reference. In addition, the sum must also show an absolute increase of at least 5 mm. Stable disease (SD) was defined as the sum of diameters of eligible lesions between the defined PR or PD.

[0350] The appearance of new non-target lesions during participation in this study does not constitute progressive disease.

[0351] Pain in the treated area will be measured by a numeric rating scale (NRS-11). Changes in pain from baseline to day 43 will be analyzed.

[0352] Systemic exposure is determined by the following factors: T 最大 , C 最大 , AUC.

[0353] Preliminary results: Preliminary results from the ongoing study include photos of metastatic lesions on the skin of the chest of women with stage 4 breast cancer. Figure 5 is a photograph taken at baseline (Day 1) showing the indicated lesion (arrow) covered with coagulated exudate from an ulcerated lesion. Figure 6 This is a photograph taken on day 8 after topical treatment with formulation F14 (0.15%) applied twice daily to the same treatment site. The lesion surface contained excoriations and areas of presumed ulceration confined to the dermis. Figure 7 This is a photograph taken on day 15 after topical treatment with formulation F14 (0.15%) applied twice daily to the same treatment site. A small amount of old exudate can be seen in the middle part of the lesion, and there is no obvious epidermal ulceration. Figure 8 This is a photograph taken on day 29 after topical treatment with formulation F14 (0.15%) applied twice daily to the same treatment site. The lesion appears to have epithelialized with no signs of ulceration. In contrast, the natural history of ulcerated cutaneous breast cancer metastases is rapid enlargement and further penetration of the dermis once the epidermal surface is breached by the tumor. Thus, topical application of therapeutic formulations for cutaneous metastatic disease provides a benefit to the patient.

[0354] Example 13 - Dermal Toxicity Study

[0355] Dermal toxicity studies were performed using the formulations shown in Table 20.

[0356] Table 20

[0357]

[0358] exist A GLP compliance study was conducted in minipigs to characterize the toxicity of formulations applied topically daily to 10% of body surface area for 28 days. The 4 formulations shown in Table 20 were administered at the maximum feasible volume of 2 mL / kg, which was associated with dose concentrations of 0.0%, 0.3%, 1.0%, and 3%, corresponding to dose levels of 0 mg / kg / day, 4.9 mg / kg / day, 16.5 mg / kg / day, and 49.9 mg / kg / day, respectively. The reversibility of the findings was also assessed after a 2-week recovery period. The parameters assessed included clinical observations, mortality and mortality examinations, dermal scores, body weights, food consumption, ocular examinations, test site photographs, electrocardiograms, clinical pathology, bioanalytical and toxicokinetic assessments, organ weights, macroscopic pathology, and histopathology. There were no formulation-related effects on survival, clinical symptoms, dermal irritation, body weight, weight gain, food consumption, ophthalmic examination results, or cardiac parameters. Minimal dermal irritation was observed in all groups during the dosing phase, which was considered to be vehicle or procedure related, as the frequency and severity of findings were comparable between the placebo control group and the active formulation treatment groups. Therefore, the presence of paclitaxel nanoparticles in the formulation had a negligible effect on dermal irritation.

Claims

1. Use of a composition comprising a hydrophobic carrier and a plurality of taxane nanoparticles for the preparation of a medicament for treating a skin malignancy in a subject in need of such treatment, wherein the composition comprising a hydrophobic carrier and a plurality of taxane nanoparticles is for topical administration to an affected area of ​​the subject, wherein the plurality of taxane nanoparticles are uncoated, original, individual particles of taxane, wherein the plurality of taxane nanoparticles are not bound to any substance. 2 . The use according to claim 1 , wherein the plurality of taxane nanoparticles have a solubility in water of less than or equal to 10 mg / mL at room temperature.

3. The use according to claim 1, wherein the taxane nanoparticles are in crystalline form. The use according to claim 1 , wherein the taxane nanoparticles are in a non-crystalline form. 5 . The use according to claim 1 , wherein the taxane nanoparticles have an average particle size based on number average distribution of 0.1 μm to 1.5 μm. The use according to claim 1 , wherein the taxane is paclitaxel.

7. The use according to claim 6, wherein the taxane nanoparticles have a m 2 / g to 40m 2 / g specific surface area (SSA).

8. The use according to claim 7, wherein the taxane nanoparticles contain not less than 90% by weight of paclitaxel.

9. The use according to claim 1, wherein the composition comprises 0.1% w / w to 5% w / w of the plurality of taxane nanoparticles.

10. The use according to claim 1, wherein the taxane nanoparticles are suspended in the composition.

11. The use according to claim 1, wherein the composition is anhydrous.

12. The use according to claim 1, wherein the composition comprises greater than 50% w / w of the hydrophobic carrier.

13. The use according to claim 1, wherein the hydrophobic carrier is non-volatile and non-polar.

14. The use according to claim 1, wherein the hydrophobic carrier comprises a hydrocarbon.

15. Use according to claim 14, wherein the hydrocarbon is petrolatum, mineral oil or paraffin or a mixture thereof.

16. The use according to claim 1, wherein the composition is an emulsion.

17. The use according to claim 16, wherein the emulsion is a water-in-oil emulsion.

18. The use according to claim 16, wherein the emulsion is an oil-in-water emulsion.

19. The use according to claim 1, wherein the composition comprises one or more than one volatile silicone fluid.

20. Use according to claim 19, wherein the composition comprises from 5% w / w to 24% w / w of one or more than one volatile silicone fluid.

21. The use according to claim 19, wherein the one or more than one volatile silicone fluid comprises cyclomethicone.

22. The use according to claim 1, wherein the composition does not contain C1 to C4 fatty alcohols, surfactants, proteins or hyaluronic acid-taxane conjugates.

23. The use according to claim 1, wherein the skin malignancy is skin cancer.

24. The use according to claim 23, wherein the skin cancer is melanoma, basal cell carcinoma, squamous cell carcinoma or Kaposi's sarcoma.

25. The use according to claim 1, wherein the skin malignancy is a skin metastasis.

26. The use according to claim 25, wherein the skin metastases are from lung cancer, breast cancer, colon cancer, oral cancer, ovarian cancer, kidney cancer, esophageal cancer, gastric cancer, liver cancer or Kaposi's sarcoma.

27. A method of inhibiting the growth of crystalline taxane nanoparticles, the method comprising contacting the taxane nanoparticles with a hydrophobic carrier, wherein the hydrophobic carrier comprises a hydrocarbon.